---
document_datetime: 2023-09-21 19:29:35
document_pages: 65
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/trelegy-ellipta-h-c-ws-1369-epar-assessment-report-variation_en.pdf
document_name: trelegy-ellipta-h-c-ws-1369-epar-assessment-report-variation_en.pdf
version: success
processing_time: 48.3542948
conversion_datetime: 2025-12-26 21:11:29.894125
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

20 September 2018 EMA/630775/2018 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

Procedure No. EMEA/H/C/WS1369

Medicinal products authorised through the centralised procedure

| Invented name:   | International non- proprietary name/Common name:   | Product-specific application number   |
|------------------|----------------------------------------------------|---------------------------------------|
| Elebrato Ellipta | fluticasone furoate / umeclidinium / vilanterol    | EMEA/H/C/004781/WS1369/0001           |
| Trelegy Ellipta  | fluticasone furoate / umeclidinium / vilanterol    | EMEA/H/C/004363/WS1369/0001           |

Worksharing applicant (WSA): GlaxoSmithKline Trading Services Limited

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                   | 6                                                                                                         |
|----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ..................................................................................................6 |                                                                                                           |
| 1.2. Steps taken for the assessment of the product                                                                         | ........................................................6                                                 |
| 2. Scientific discussion................................................................................                   | 7                                                                                                         |
| 2.1. Introduction                                                                                                          | ........................................................................................................7 |
| 2.2. Rationale for the proposed change                                                                                     | .........................................................................7                                |
| 2.3. Non-clinical aspects..............................................................................................8   |                                                                                                           |
| 2.3.1. Ecotoxicity/environmental risk assessment...........................................................8               |                                                                                                           |
| 2.3.2. Discussion on non-clinical aspects                                                                                  | ..................................................................... 10                                  |
| 2.3.3. Conclusion on the non-clinical aspects                                                                              | ............................................................... 10                                        |
| 2.4. Clinical aspects ..................................................................................................   | 10                                                                                                        |
| 2.4.1. Introduction....................................................................................................    | 10                                                                                                        |
| 2.4.2. Pharmacokinetics                                                                                                    | ............................................................................................ 11           |
| 2.4.3. Discussion on clinical pharmacology...................................................................              | 12                                                                                                        |
| 2.4.4. Conclusions on clinical pharmacology.................................................................               | 13                                                                                                        |
| 2.5. Clinical efficacy                                                                                                     | .................................................................................................. 13     |
| 2.5.1. Discussion on clinical efficacy............................................................................         | 41                                                                                                        |
| 2.5.2. Conclusions on the clinical efficacy ....................................................................           | 43                                                                                                        |
| 2.6. Clinical safety                                                                                                       | .................................................................................................... 43   |
| 2.6.1. Discussion on clinical safety..............................................................................         | 54                                                                                                        |
| 2.6.2. Conclusions on clinical safety ............................................................................         | 56                                                                                                        |
| 2.6.3. PSUR cycle                                                                                                          | ..................................................................................................... 56  |
| 2.7. Risk management plan                                                                                                  | ....................................................................................... 56                |
| 2.8. Update of the Product information........................................................................             | 56                                                                                                        |
| 2.8.1. User consultation                                                                                                   | ............................................................................................ 59           |
| 3. Benefit-Risk Balance.............................................................................                       | 59                                                                                                        |
| 3.1. Therapeutic Context ...........................................................................................       | 59                                                                                                        |
| 3.1.1. Disease or condition                                                                                                | ........................................................................................ 59               |
| 3.1.2. Available therapies and unmet medical need.......................................................                   | 59                                                                                                        |
| 3.1.3. Main clinical studies.........................................................................................      | 60                                                                                                        |
| 3.2. Favourable effects..............................................................................................      | 60                                                                                                        |
| 3.3. Uncertainties and limitations about favourable effects.............................................                   | 61                                                                                                        |
| 3.4. Unfavourable effects...........................................................................................       | 61                                                                                                        |
| 3.5. Uncertainties and limitations about unfavourable effects                                                              | ......................................... 62                                                              |
| 3.6. Effects Table......................................................................................................   | 62                                                                                                        |
| 3.7. Benefit-risk assessment and discussion.................................................................               | 62                                                                                                        |
| 3.7.1. Importance of favourable and unfavourable effects..............................................                     | 62                                                                                                        |
| 3.7.2. Balance of benefits and risks ............................................................................          | 63                                                                                                        |
| 3.8. Conclusions.......................................................................................................    | 63                                                                                                        |

<div style=\"page-break-after: always\"></div>

4. Recommendations  ................................................................................. 63

5. EPAR changes ....................................................................................... 64

<div style=\"page-break-after: always\"></div>

## List of abbreviations

* This is a general list of abbreviations. Not all abbreviations will be used.

ADME

absorption, distribution, metabolism, and excretion

ADR

Adverse Drug Reaction

AE

adverse event

AESI

adverse event of special interest

ALT

alanine aminotransferase

APSD

aerodynamic particle size distribution

AST

aspartate aminotransferase

ATS

American Thoracic Society

BMI

body mass index

BUD

budesonide

CAT

COPD Assessment Test

CDLM

Capacity of Daily Living during the Morning

CEC

Clinical Endpoint Committee

CHMP

Committee for Medicinal Products for Human Use

CI

confidence interval

COPD

chronic obstructive pulmonary disease

CPRD

Clinical Practice Research Database

CRF/eCRF

case report form/electronic case report form

CSR

clinical study report

CT

computed tomography

CV

cardiovascular

ECG

electrocardiogram

EMA

European Medicines Agency

EPAR

European Public Assessment Report

ERS

European Respiratory Society

EU

European Union

EXACT-RS

Exacerbations of Chronic Pulmonary Disease Tool - Respiratory Symptoms

EXT

Extension (Population)

FDA

Food and Drug Administration

FEV1

forced expiratory volume in one second

FF

fluticasone furoate

FOR

formoterol

FP

fluticasone propionate

FVC

forced vital capacity

GCP

Good Clinical Practice

GOLD

Global Initiative for Chronic Obstructive Lung Disease

GSK

GlaxoSmithKline

HPA

hypothalamic-pituitary-adrenal

HR

hazard ratio

HRQoL

health-related quality of life

ICH

International Conference on Harmonisation

ICS

inhaled corticosteroid

IND

Investigational New Drug

ITT

Intent-to-Treat (Population)

kg

kilogram

LABA

long-acting beta 2  receptor agonist

LAMA

long-acting muscarinic receptor antagonist

LRTI

lower respiratory tract infection

LS

least square

MAA

Marketing Authorisation Application

MACE

Major Adverse Cardiac Event

mcg

milligram

MCID

minimum clinically important difference

MedDRA

Medical Dictionary for Regulatory Activities

MI

myocardial infarction

mMRC

modified Medical Research Council

NDA

New Drug Application

NHANES

National Health and Nutrition Examination Survey

PD

pharmacodynamic

PK

pharmacokinetic

PRAC

Pharmacovigilance Risk Assessment Committee

PRO

patient-reported outcomes

PT

Preferred Term

QTc(F)

corrected QT interval using Friedicia's formula

RAP

Reporting and Analysis Plan

RMP

Risk Management Plan

SAE

serious adverse event

SALM

salmeterol

SAR

serious adverse report

SAWP

Scientific Advice Working Party

SD

standard deviation

SDAP

Summary Document Analysis Plan

SE

standard error

SGRQ

St. George's Respiratory Questionnaire

SGRQ-C

St. George's Respiratory Questionnaire for COPD

SmPC

Summary of Product Characteristics

SMQs

Standardised MedDRA Queries

SS

Serial Spirometry (Population)

TDI

Transitional Dyspnoea Index

TDI-SAC

Transitional Dysponea Index-self administered computerised version

TIO

tiotropium

UK

United Kingdom

UMEC

umeclidinium bromide

URTI

upper respiratory tract infection

US

United States

VI

vilanterol

WM

weighted mean

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, GlaxoSmithKline Trading Services Limited submitted to the European Medicines Agency on 13 February 2018 an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extention of indication to modify the therapeutic indication for Elebrato Ellipta and Trelegy Ellipta into \"maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD)\".

As a consequence, the indication section (4.1), Undesirable effects section (4.8) and Pharmacodynamic Properties section (5.1), Pharmacokinetic properties section (5.2), Preclinical Safety data section (5.3) of the EU SmPC are updated. This is based on the result of study CTT116855 and study 200812 and the population PK report 208059.

The Package Leaflet is updated in accordance.

Additionally, an updated RMP (version 2.0) has also been submitted to introduce minor changes and bring it in line with the new template (rev.2).

The requested worksharing procedure proposed amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) CW/0001/2015 on the granting of a class waiver.

## Scientific advice

The MAH did not seek Scientific Advice at the CHMP.

## 1.2. Steps taken for the assessment of the product

Appointed (Co-)Rapporteurs for the WS procedure:

Peter Kiely

Harald Enzmann

<div style=\"page-break-after: always\"></div>

| Timetable                                            | Actual dates         |
|------------------------------------------------------|----------------------|
| Submission date                                      | 13 February 2018     |
| Start of procedure:                                  | 3 March 2018         |
| CHMP Rapporteur Assessment Report                    | 2 May 2018           |
| CHMP Co-Rapporteur Assessment Report                 | 28 April 2018        |
| PRAC Rapporteur Assessment Report                    | 3 May 2018           |
| PRAC members comments                                | 7 May 2018           |
| PRAC Outcome                                         | 17 May 2018          |
| CHMP members comments                                | 22 May 2018          |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | 25 May 2018          |
| Request for supplementary information (RSI)          | 31 May 2018          |
| CHMP Rapporteur Assessment Report                    | 21 August 2018       |
| PRAC Rapporteur Assessment Report                    | 24 August 2018       |
| PRAC members comments                                | 12 September 2018    |
| Updated PRAC Rapporteur Assessment Report            | 6 September 2018     |
| PRAC Outcome                                         | 6 September 2018     |
| CHMP members comments                                | 10,11 September 2018 |
| Updated CHMP Rapporteur Assessment Report            | 14 September 2018    |
| Opinion                                              | 20 September 2018    |

## 2. Scientific discussion

## 2.1. Introduction

FF/UMEC/VI (Trelegy Ellipta, Elebrato Ellipta) once-daily was approved in the European Union (EU) on 15 November  2017  as  a  maintenance  treatment  in  adult  patients  with  moderate  to  severe  chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and LABA.  FF is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity, UMEC is a long acting muscarinic antagonist (LAMA) and VI is a selective long-acting, beta2-adrenergic agonist (LABA).

## 2.2. Rationale for the proposed change

The purpose of this variation application is to update the license for Trelegy Ellipta and Elebrato Ellipta to provide information relating to the comparison of FF/UMEC/VI with FF/VI and UMEC/VI, the comparison of FF/UMEC/VI with the open combination of FF/VI + UMEC, and the pharmacokinetics (PK) of FF, UMEC, and  VI  following  inhalation  of  FF/UMEC/VI  in  patients  with  COPD.  Specific  revisions  to  the  SmPC  are proposed for Section 4.1 Therapeutic indications, Section 4.8 Undesirable effects, Section 5.1 Pharmacodynamic properties (Clinical Efficacy), and Section 5.2 Pharmacokinetic properties.

FF/UMEC/VI (Trelegy Ellipta,  Elebrato  Ellipta)  once-daily  is  approved  in  the  European  Union  (EU)  as  a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and LABA.

<div style=\"page-break-after: always\"></div>

The company is submitting a revised indication wording with changes strikethrough as follows :

Trelegy Ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist (for effects on symptom control see section 5.1).

The revisions are primarily based on data from Study CTT116855 (IMPACT) that compared FF/UMEC/VI with FF/VI and UMEC/VI over 52 weeks in subjects with COPD using a primary endpoint of the annual rate of on-treatment moderate/severe exacerbations.  Additional revisions are based on data from Study 200812  evaluating  the  non-inferiority  FF/UMEC/VI  compared  with  UMEC  +  FF/VI  over  24  weeks  in subjects with COPD and data from a population PK analysis (Study 208059) of FF, UMEC, and VI when administered from a single inhaler as FF/UMEC/VI or from separate inhalers as UMEC + FF/VI in subjects with COPD.

Changes have been proposed in the SmPC for sections 4.1, 5.1 &amp; 5.2 &amp; 5.3, with an updated AE table in section 4.8. The PL is amended accordingly.

## 2.3. Non-clinical aspects

No new clinical data have been submitted in this application, which  was considered acceptable by the CHMP.

However, the current wording in sections of the EU Summary of Product Characteristics (SPC) associated with nonclinical study data contains exposure multiples calculated using data from population PK analyses for FF/UMEC/VI conducted for a subset of 74 COPD subjects from study CTT116853.

Population  PK  analyses  have  been  updated  using  a  combined  dataset  from  821  COPD  subjects administered  FF/UMEC/VI  in  combination  from  studies  200812,  CTT116853  and  CTT116855  (see population  PK  report).  Using  exposure  values  from  this  larger  data  set  has  added  robustness  to  the exposure multiples calculated for each active component when comparing with animal systemic exposure data.  It  is  proposed  to  revise  the  nonclinical  related  exposure  multiples  in  the  SPC  accordingly,  thus aligning  with  other  references  to  the  3-study  combined  population  PK  analysis-derived  values  in  the current submission.

This  was  reviewed  and  agreed  upon.  Therefore  the  section  5.3  is  updated  to  include  the  updated genotoxicity, carcinogenicity and reproductive toxicity figures.

## 2.3.1. Ecotoxicity/environmental risk assessment

An updated tailored Phase II Tier A environmental risk assessment was provided for the active ingredient fluticasone furoate (FF). For the active ingredients umeclidinium (UMEC) and vilanterol (VI) an update of the Phase I environmental risk assessments was not necessary.

Environmental  Risk  Assessments  (ERAs)  for  all  three  ingredients  have  been  previously  undertaken  in monotherapy and different combinations undertaken which have all been reviewed and approved in the EU via the Centralised Procedures.

The risk characterization has been updated by new sales data (total sales of FF in all medical products in the EU (IMS 2016: 74 kg) and 5 years forecast in EU).

PECsw-refined based on manufacturing forecast of all GSK registered products for the 5th year of sales in the EU is 0.0011 µg/L or 1.1 ng/L.

<div style=\"page-break-after: always\"></div>

Table 1: PECgroundwater-refined = 0.25 x PECsw-refined = 0.00027 ng/L.

| Matrix                 |   PEC [µg/L] | Species   |   NOEC [µg/L] |   AF |   PNEC [µg/L] |   PEC/PNEC | Result   |
|------------------------|--------------|-----------|---------------|------|---------------|------------|----------|
| Surface water- refined |     0.0011   | Fish      |          0.29 |   10 |         0.029 |    0.038   | No risk  |
| Groundwater- refined   |     0.000275 | Daphnia   |         12    |   10 |         1.2   |    0.00023 | No risk  |

Table 2: Summary of main study results

| Substance (INN/Invented Name): Fluticasone furoate (GW685698) CAS-number (if available): 397864-44-7   | Substance (INN/Invented Name): Fluticasone furoate (GW685698) CAS-number (if available): 397864-44-7                                                                                                                                               | Substance (INN/Invented Name): Fluticasone furoate (GW685698) CAS-number (if available): 397864-44-7                                                                                                                                               | Substance (INN/Invented Name): Fluticasone furoate (GW685698) CAS-number (if available): 397864-44-7                                                                                                                                               | Substance (INN/Invented Name): Fluticasone furoate (GW685698) CAS-number (if available): 397864-44-7                                                                                                                                               | Substance (INN/Invented Name): Fluticasone furoate (GW685698) CAS-number (if available): 397864-44-7   |
|--------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|
| PBT screening                                                                                          |                                                                                                                                                                                                                                                    | Result                                                                                                                                                                                                                                             | Result                                                                                                                                                                                                                                             | Result                                                                                                                                                                                                                                             | Conclusion                                                                                             |
| Bioaccumulation potential- log K ow                                                                    | OECD117                                                                                                                                                                                                                                            | 2.61                                                                                                                                                                                                                                               | 2.61                                                                                                                                                                                                                                               | 2.61                                                                                                                                                                                                                                               | Potential PBT (N)                                                                                      |
| PBT-assessment                                                                                         | PBT-assessment                                                                                                                                                                                                                                     | PBT-assessment                                                                                                                                                                                                                                     | PBT-assessment                                                                                                                                                                                                                                     | PBT-assessment                                                                                                                                                                                                                                     | PBT-assessment                                                                                         |
| Parameter                                                                                              | Result relevant for conclusion                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                    | Conclusion                                                                                             |
| Bioaccumulation                                                                                        | log K ow                                                                                                                                                                                                                                           | 2.61                                                                                                                                                                                                                                               | 2.61                                                                                                                                                                                                                                               | 2.61                                                                                                                                                                                                                                               | not B                                                                                                  |
| Persistence                                                                                            | OECD 304 A                                                                                                                                                                                                                                         | DT50 > 137 d (12°C)                                                                                                                                                                                                                                | DT50 > 137 d (12°C)                                                                                                                                                                                                                                | DT50 > 137 d (12°C)                                                                                                                                                                                                                                | P                                                                                                      |
| Toxicity                                                                                               | NOEC                                                                                                                                                                                                                                               | 0.29 µg/L                                                                                                                                                                                                                                          | 0.29 µg/L                                                                                                                                                                                                                                          | 0.29 µg/L                                                                                                                                                                                                                                          | T                                                                                                      |
| PBT-statement :                                                                                        | The compound is not considered as PBT nor vPvB                                                                                                                                                                                                     | The compound is not considered as PBT nor vPvB                                                                                                                                                                                                     | The compound is not considered as PBT nor vPvB                                                                                                                                                                                                     | The compound is not considered as PBT nor vPvB                                                                                                                                                                                                     | The compound is not considered as PBT nor vPvB                                                         |
| Phase I                                                                                                | Phase I                                                                                                                                                                                                                                            | Phase I                                                                                                                                                                                                                                            | Phase I                                                                                                                                                                                                                                            | Phase I                                                                                                                                                                                                                                            | Phase I                                                                                                |
| Calculation                                                                                            | Value                                                                                                                                                                                                                                              | Unit                                                                                                                                                                                                                                               | Unit                                                                                                                                                                                                                                               | Unit                                                                                                                                                                                                                                               | Conclusion                                                                                             |
| PEC surfacewater , refined on 5 years sales forecast for EU                                            | 0.0011                                                                                                                                                                                                                                             | µ g/L                                                                                                                                                                                                                                              | µ g/L                                                                                                                                                                                                                                              | µ g/L                                                                                                                                                                                                                                              | > 0.01 threshold (N)                                                                                   |
| Other concerns (e.g. chemical class)                                                                   | Fluticasone furoate is a glucocorticoid and, as such, is considered a potential endocrine disruptor and therefore the potential endocrine activity of this compound was investigated in an appropriate chronic test system with relevant endpoints | Fluticasone furoate is a glucocorticoid and, as such, is considered a potential endocrine disruptor and therefore the potential endocrine activity of this compound was investigated in an appropriate chronic test system with relevant endpoints | Fluticasone furoate is a glucocorticoid and, as such, is considered a potential endocrine disruptor and therefore the potential endocrine activity of this compound was investigated in an appropriate chronic test system with relevant endpoints | Fluticasone furoate is a glucocorticoid and, as such, is considered a potential endocrine disruptor and therefore the potential endocrine activity of this compound was investigated in an appropriate chronic test system with relevant endpoints | (Y)                                                                                                    |
| Phase II Physical-chemical properties and fate                                                         | Phase II Physical-chemical properties and fate                                                                                                                                                                                                     | Phase II Physical-chemical properties and fate                                                                                                                                                                                                     | Phase II Physical-chemical properties and fate                                                                                                                                                                                                     | Phase II Physical-chemical properties and fate                                                                                                                                                                                                     | Phase II Physical-chemical properties and fate                                                         |
| Study type                                                                                             | Test protocol                                                                                                                                                                                                                                      | Results                                                                                                                                                                                                                                            | Results                                                                                                                                                                                                                                            | Results                                                                                                                                                                                                                                            | Remarks                                                                                                |
| Adsorption-Desorption                                                                                  | OECD 106                                                                                                                                                                                                                                           | Koc = 3,800 to 16,000mL/g (mean of 4 soils and 1 sediment: 9,600mL/g) Koc des = 5,400 to 22,000mL/g (mean of 4 soils and 1 sediment: 13,000mL/g)                                                                                                   | Koc = 3,800 to 16,000mL/g (mean of 4 soils and 1 sediment: 9,600mL/g) Koc des = 5,400 to 22,000mL/g (mean of 4 soils and 1 sediment: 13,000mL/g)                                                                                                   | Koc = 3,800 to 16,000mL/g (mean of 4 soils and 1 sediment: 9,600mL/g) Koc des = 5,400 to 22,000mL/g (mean of 4 soils and 1 sediment: 13,000mL/g)                                                                                                   | Report provided                                                                                        |
| Inherent Biodegradability Test                                                                         | OECD 302 C                                                                                                                                                                                                                                         | Not inherently biodegradable                                                                                                                                                                                                                       | Not inherently biodegradable                                                                                                                                                                                                                       | Not inherently biodegradable                                                                                                                                                                                                                       | Report provided                                                                                        |
| Inherent biodegradability in Soil                                                                      | OECD 304 A                                                                                                                                                                                                                                         | DT50 > 64d 3% mineralization in 64d                                                                                                                                                                                                                | DT50 > 64d 3% mineralization in 64d                                                                                                                                                                                                                | DT50 > 64d 3% mineralization in 64d                                                                                                                                                                                                                | Reliable Report provided FF considered as P                                                            |
| Phase IIa Effect studies                                                                               | Phase IIa Effect studies                                                                                                                                                                                                                           | Phase IIa Effect studies                                                                                                                                                                                                                           | Phase IIa Effect studies                                                                                                                                                                                                                           | Phase IIa Effect studies                                                                                                                                                                                                                           | Phase IIa Effect studies                                                                               |
| Study type                                                                                             | Test protocol                                                                                                                                                                                                                                      | Endpoint                                                                                                                                                                                                                                           | value                                                                                                                                                                                                                                              | Unit                                                                                                                                                                                                                                               | Remarks                                                                                                |
| Acute toxicity to Daphnia magna                                                                        | OECD 202                                                                                                                                                                                                                                           | NOEC                                                                                                                                                                                                                                               | 4.2 (unfiltered 48h) 0.012 (filtered 48h)                                                                                                                                                                                                          | mg/L                                                                                                                                                                                                                                               | Report provided Not valid and not relevant for this ERA.                                               |
| Fish, Early Life Stage Toxicity Test/ Pimephales promelas                                              | OECD 210                                                                                                                                                                                                                                           | NOEC                                                                                                                                                                                                                                               | 0.29                                                                                                                                                                                                                                               | µg/L                                                                                                                                                                                                                                               | Report provided                                                                                        |
| Activated Sludge, Respiration Inhibition Test                                                          | OECD 209                                                                                                                                                                                                                                           | NOEC                                                                                                                                                                                                                                               | 1000                                                                                                                                                                                                                                               | mg/L                                                                                                                                                                                                                                               | Report provided                                                                                        |
| Phase IIb Studies                                                                                      | Phase IIb Studies                                                                                                                                                                                                                                  | Phase IIb Studies                                                                                                                                                                                                                                  | Phase IIb Studies                                                                                                                                                                                                                                  | Phase IIb Studies                                                                                                                                                                                                                                  | Phase IIb Studies                                                                                      |
| Earthworm, Acute Toxicity Tests                                                                        | OECD 207                                                                                                                                                                                                                                           | NOEC                                                                                                                                                                                                                                               | 1000                                                                                                                                                                                                                                               | mg/kg                                                                                                                                                                                                                                              | Eisenia fetida LC 50 (14 days) = 1,000 mg/kg Report                                                    |

<div style=\"page-break-after: always\"></div>

| provided   |
|------------|

## 2.3.2. Discussion on non-clinical aspects

The  outcome  of  the  updated  refined  risk  characterisation  shows  that  fluticasone  furoate  is  unlikely  to present  a  relevant  risk  to  organisms  in  the  aquatic  environment  and  in  groundwater  when  fluticasone furoate will reach surface waters via wastewater by the use of the maximum recommended dose.

Therefore, further testing in the aquatic compartment will not be necessary and it can be concluded that the drug substance and/or its metabolites are unlikely to represent a risk to the aquatic environment.

## 2.3.3. Conclusion on the non-clinical aspects

The updated data submitted in this application do not lead to a significant increase in environmental exposure further to the use of fluticasone furoate, umeclidinium (UMEC) and vilanterol. In addition, updated figures are also inserted in section 5.3 of the Product Information for each monocomponent based on the population PK analyses submitted in the present application.

## 2.4. Clinical aspects

## 2.4.1. Introduction

The  MAH  is  submitting  this  application  to  update  the  marketing  authorisation  for  both  Trelegy  and Elebrato,  based  on  the  results  of  study  CTT116855  and  study  200812  and  the  population  PK  report 208059.

Study CTT116855 was a randomised, double-blind, parallel-group study that compared the efficacy and safety  of  FF/UMEC/VI  with  FF/VI  and  UMEC/VI  for  52  weeks  in  subjects  with  COPD.  This  study  was designed to evaluate the benefit of FF/UMEC/VI over the FF/VI and UMEC/VI dual component medications in subjects with advanced, symptomatic COPD and at risk of exacerbation using a primary endpoint of the annual rate of on-treatment moderate/severe COPD exacerbations.

Study 200812 was a randomised, double blind, parallel group study comparing FF/UMEC/VI administered in  one  Ellipta  inhaler  with  FF/VI  +  UMEC  administered  in  separate  Ellipta  inhalers  over  24  weeks  in subjects  with  COPD.  This  study  was  designed  to  demonstrate  the  non-inferiority  of  FF/UMEC/VI  to FF/VI+UMEC using a primary endpoint of trough FEV1 at Week 24 with a margin of non-inferiority of 50 mL.

The population PK analysis (Study 208059) evaluated combined data from a subset of COPD patients that participated  in  3  phase  IIIa/b  studies  (CTT116855,  CTT116853,  200812)  to characterise  the  PK of  FF, UMEC and VI following administration of FF/UMEC/VI or from separate inhalers as UMEC + FF/VI or as dual  FF/VI  or  UMEC/VI  from  an  Ellipta  inhaler  and  to  assess  the  effect  of  covariates  on  the  PK  of  FF, UMEC and VI.

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

<div style=\"page-break-after: always\"></div>

## 2.4.2. Pharmacokinetics

## Pharmacokinetic interaction studies

The report of a population PK analysis (Study 208059) of FF, UMEC, and VI when administered from a single inhaler as FF/UMEC/VI or from separate inhalers as UMEC + FF/VI or as dual FF/VI or UMEC/VI in subjects with COPD is presented.

The primary objectives of the analyses were:

- to characterize the population PK of FF, UMEC and VI in adults with COPD following administration of  FF/UMEC/VI  in  an  ELLIPTA  inhaler  and  following  administration  of  FF/VI+UMEC,  FF/VI, UMEC/VI.
- to  identify  influential  covariates,  among  age,  race,  gender,  weight,  body  mass  index,  smoking status,  concurrent  medications  (cytochrome  P450  inducers/inhibitors,  Pgp  inhibitors),  lung function  status  in  terms  of  reversibility  post  albuterol/salbutamol,  percent  predicted  FEV1  at screening (PPFEV1) and creatinine clearance on the PK of FF, UMEC and VI in patients with COPD.

The primary endpoints of the analyses were:

- Non-linear  mixed  effects  model  (NONMEM)  generated  post-hoc  estimates  for  FF,  UMEC  and  VI population PK parameters and associated inter-subject variability and residual error: (Apparent clearance [CL/F], apparent volume of distribution (V/F), absorption rate constant [Ka]).
- Derived PK parameters: Area under the curve at steady state (AUC(ss)) and Cmax.

## Methods

FF, UMEC and VI plasma concentration - time data were used for population PK analyses using non-linear mixed  effects  modelling  with  NONMEM  v7.4.  A  model-based  estimation  approach  was  undertaken whereby the plasma data for FF, UMEC and VI from Studies 200812, CTT116853 and CTT116855 were combined.  The previously reported population PK models for FF, UMEC and VI served as starting points for the structural model development (adequacy was assessed using Monte Carlo simulations).  The data below the limit of quantification (BLQ) were treated as censored data and all data were analysed with the full likelihood approach (M3 method). Covariate analysis was undertaken once the base structural model had been developed. The adequacies of the population PK models were assessed through diagnostic plots and visual predictive checks.  The post-hoc individual parameter estimates from each model for FF, UMEC and VI were utilized to estimate individual systemic exposure measures.  The geometric mean and the associated 95% confidence intervals (CIs) for AUCss and Cmax at steady state were summarized for each analyte by study, treatment, geographic race and region.

## Results

Analysis  Population:  A  total  of  821  subjects  from  3  studies  contributed  to  population  PK  analysis. Demographic  and  baseline  characteristics  of  subjects  were  similar  across  each  of  the  3  population  PK datasets (FF, UMEC and VI).

The PK of FF in 200812, CTT116853 and CTT116855 was well-described by a two-compartment model with  first-order  absorption  and  first-order  elimination.  The  only  covariates  found  to  be  statistically

<div style=\"page-break-after: always\"></div>

significant  were  Japanese  heritage  and  FF/VI  treatment  on  inhaled  clearance  (CL/F)  but  no  dose adjustment was warranted based on the predicted systemic exposure.

The PK of UMEC in 200812, CTT116853 and CTT116855 was well-described by a two-compartment model with first-order absorption and first-order elimination. Weight, age and smoking status were found to be significant  covariates  on  CL/F  and  weight  was  also  a  significant  covariate  on  the  apparent  volume  of distribution of the central compartment (V2/F). However, no dose adjustment was warranted for these covariates based on the predicted systemic exposure.

The PK of VI in 200812, CTT116853 and CTT116855 was well-described by a two-compartment model with  first-order  absorption  and  first-order  elimination.  Weight  and  smoking  status  were  found  to  be significant covariates on CL/F and V2/F, respectively. However, no dose adjustment was warranted for these covariates based on the predicted systemic exposures.

The final parameter estimates for the three population PK models are presented in the Table below.

Table 3: Final Population PK Model Parameters

| FF                        | FF                     | UMEC                    | UMEC                     | VI                      | VI                   |
|---------------------------|------------------------|-------------------------|--------------------------|-------------------------|----------------------|
| Parameter                 | Estimate [95% CI]      | Parameter               | Estimate [95% CI]        | Parameter               | Estimate [95% CI]    |
| CL/F [L/h]                | 513 [493, 534]         | CL/F [L/h]              | 149 [138, 160]           | CL/F [L/h]              | 73.5 [69.7, 77.3]    |
| V2/F [L]                  | 1.36 FIXED             | V2/F [L]                | 1100 [1030, 1170]        | V2/F [L]                | 352 [333, 371]       |
| Q/F [L/h]                 | 268FIXED               | Q/F [L/h]               | 854 FIXED                | Q/F [L/h]               | 242 [230, 254]       |
| V3/F [L]                  | 111 FIXED              | V3/F [L]                | 16200FIXED               | V3/F [L]                | 2250 [1670, 2830]    |
| KA [h-1]                  | 0.0821 [0.0805,0.0837] | KA [h-1]                | 18.6 [16.2, 21.0]        | KA [h-1]                | 19.6 FIXED           |
| Japanese heritage on CL/F | 0.647 [0.628, 0.666]   | Weight exponent on CL/F | 0.580 [0.409, 0.751]     | Weight exponent on CL/F | 0.444 [0.281, 0.607] |
| FF/VI on CL/F             | 1.42 [1.38, 1.46]      | Age exponent on CL/F    | -0.648 [-0.979, - 0.317] | Smoking effect on V2/F  | 1.46 [1.34, 1.59]    |
|                           |                        | Smoking effect on CL/F  | 1.28 [1.13, 1.45]        |                         |                      |
|                           |                        | Weight exponent on V2/F | 0.797 [0.614, 0.980]     |                         |                      |

## 2.4.3. Discussion on clinical pharmacology

The report of a population PK analysis (Study 208059) of FF, UMEC, and VI when administered from a single inhaler as FF/UMEC/VI or from separate inhalers as UMEC + FF/VI or as dual FF/VI or UMEC/VI in 821 subjects with COPD is submitted.

A  total  of  821  subjects  from  3  studies  provided  samples  for  the  population  PK  analysis.  Data  for  few subjects (16/821= 2%), at one or both visits could not be utilized due to discrepancy between dosing time record and PK sample collection time record and were considered as protocol deviations. There were 714, 622, and 817 COPD subjects with that contributed to final FF, UMEC and VI population PK datasets respectively from the combined data from CTT116855, 200812 and CTT116853 studies. FF, UMEC, and VI datasets contained 2948, 2589 and 3331 plasma concentration-time observations respectively. Approximately, 13% to 41% samples were BLQ.

All FF, UMEC, VI plasma concentrations were well interspersed with historical data.

<div style=\"page-break-after: always\"></div>

FF,  UMEC  and  VI  PK  were  all  adequately  described  by  a  two-compartment  model  with  first-order absorption.

For FF, Japanese heritage and FF/VI treatment were significant covariates on apparent inhaled clearance. For UMEC, weight, age and smoking status on apparent inhaled clearance and weight on apparent volume of  distribution  were  significant  covariates.  For  VI,  weight  on  apparent  inhaled  clearance  and  smoking status on apparent volume of distribution were significant covariates.

For Japanese heritage COPD subjects, FF CL/F was estimated to be 35% lower, but the increase in FF systemic  exposure  in  subjects  of  Japanese  heritage  versus  non-Japanese  heritage  as  these  systemic exposures remain well below the threshold for FF-induced reduction of serum cortisol.

The typical value of FF CL/F was 513 L/h for subjects receiving FF/UMEC/VI (100/62.5/25 mcg). For FF/VI (100/25 mcg) administration, FF CL/F was estimated to be 42% higher. However, such values in subjects receiving  FF/VI  versus  FF/UMEC/VI  is  not  likely  to  be  clinically  relevant  as  these  systemic  exposures remain well below the threshold for FF-induced reduction of serum cortisol.

In a similar manner, no clinically relevant change in UMEC or VI systemic exposure was estimated after accounting for the effect of the influential covariates namely age, weight and smoking status.

In  summary,  population  PK  analyses  (similar  to  historical)  demonstrated  that  the  effects  of  these covariates on PK were marginal and no dose adjustment was deemed necessary for FF, UMEC or VI based on these covariates.

Steady state AUCss (geometric mean, pg*h/mL) and Cmax,ss (geometric mean, pg/mL) for FF/UMEC/VI were consistent with historical data for FF/VI and UMEC/VI and there was no clinically relevant difference in FF, UMEC or VI systemic exposure when administered as FF/UMEC/VI or UMEC+FF/VI.

## 2.4.4. Conclusions on clinical pharmacology

Population  PK  analyses  for  FF/UMEC/VI  using  combined  data  from  Studies  CTT116855,  200812  and CTT116853 were consistent with those for the components when given in dual combination. The models described  adequately  the  PK  of  FF,  UMEC  and  VI  in  patients  with  COPD.  No  dose  adjustments  are warranted based on age, weight, smoking status or race.

In conclusion, the results of the Population PK analysis are adequately reflected in the section 5.2 of the SmPC, including also an update to the elderly section.

## 2.5. Clinical efficacy

Two efficacy studies have been submitted in this variation. The MAH request for changes to the indication is based on study CTT116855 and on Study 200812 as supporting efficacy data.

The methods/design/populations will be presented separately for each study hereafter. However for the results analyses will be presented together.

## Main study - Study CTT116855

<div style=\"page-break-after: always\"></div>

## Methods

## Objective(s)

The  primary  objective  of  Study  CTT116855  was  to  evaluate  the  efficacy  of  FF/UMEC/VI  to  reduce  the annual  rate  of  moderate/severe  exacerbations  compared  with  dual  therapy  of  FF/VI  or  UMEC/VI  in subjects with COPD.

The primary objective of Study 200812 was to compare the effect of FF/UMEC/VI with FF/VI+UMEC on lung function after 24 weeks of treatment.

## Study design

CTT116855 study was a randomised, double-blind, parallel-group study that compared the efficacy and safety  of  FF/UMEC/VI  with  FF/VI  and  UMEC/VI  for  52  weeks  in  subjects  with  COPD.  This  study  was designed to evaluate the benefit of FF/UMEC/VI over the FF/VI and UMEC/VI dual component medications in subjects with advanced, symptomatic COPD and at risk of exacerbation using a primary endpoint of the annual rate of on-treatment moderate/severe COPD exacerbations.

At total of 10,355 subjects were randomized in the Intent-to-Treat (ITT) Population at study centres in 37 countries. The total duration of subject participation was approximately 55 weeks, consisting of a 2-week Run-in Period, 52-week Treatment Period, and a 1-week Safety Follow-up Period.  Clinic visits occurred at pre-screening/screening, Randomization (Day 1), and after 4, 16, 28, 40, and 52 weeks of treatment. In addition, there was a safety follow-up telephone contact or clinic visit conducted one week after completing the last study visit.

Eligible subjects were randomized (2:2:1) to the FF/UMEC/VI, FF/VI, and UMEC/VI treatment groups.

Figure 1: Study Schematic

<!-- image -->

Discussion of Study Design

Use of the FF/VI and UMEC/VI active comparator groups is consistent with the CHMP Note for Guidance on Fixed Dose Combination Medicinal Products which suggest studies be conducted preferably against the component medications [EMA/CHMP/158268/2017]. Moreover, use of these active comparators extends the previous development work that supported the approval of Trelegy Ellipta/Elebrato Ellipta by using partial factorial analysis to demonstrate the contribution of both the UMEC and FF components of Trelegy Ellipta/Elebrato  Ellipta  based  on  comparisons  of  FF/UMEC/VI  with  the  FF/VI  and  UMEC/VI  dual components,  respectively.  This  approach  was  done  in  agreement  with  Scientific  Advice  from  CHMP (EMEA/H/SA/2498/1/2012/II and EMEA/H/SA/2498/1/FU/1/2013/II).

<div style=\"page-break-after: always\"></div>

## Study population

The enrolment criteria for Study CTT116855 were consistent with those from Study CTT116853 which supported  the  initial  MAA  application.  As  Study  CTT116855  was  designed  to  assess  benefit  on exacerbations, patients with advanced, symptomatic COPD and at risk of an exacerbation were enrolled. Additionally,  CTT116855  was  intentionally  designed  to  be  as  inclusive  as  possible  with  regards  to  the enrolment of subjects with significant CV disease.  For example, subjects with a past history of previous myocardial  infarction  (MI)  (&gt;6  months  prior  to  Screening)  and  New  York  Heart  Association  Class  1-3 heart failure were eligible for inclusion in the study.  In addition, patients with first degree heart block, second degree heart block Mobitz Type 1, and corrected QT interval using Friedicia's formula (QTc[F]) measurements up to 530 msec in patients with a QRS &gt;120 msec could be enrolled.

Basic inclusion criteria were: male or female subjects, 40-years of age or older with a diagnosis of COPD, a history of cigarette smoking of ≥10 pack-years, a post-albuterol FEV1/forced vital capacity (FEV1/FVC) ratio of &lt;0.70, with symptomatic COPD based on a score of ≥10 on the CAT.  Requirements for severity of airflow obstruction and exacerbation history requirements were either:

- a post-bronchodilator FEV1 &lt; 50% predicted normal and a documented history of ≥ 1 moderate or severe COPD exacerbation in the previous 12 months or,
- a post-bronchodilator 50% ≤ FEV1 &lt; 80% predicted normal and a documented history of ≥ 2 moderate  COPD  exacerbations  or  a  documented  history  of  ≥  1  severe  COPD  exacerbation (hospitalized) in the previous 12 months.

Additionally,  consistent  with  CHMP  follow-up  advice  on  the  study  design,  subjects  must  have  been receiving daily maintenance treatment for their COPD for at least 3 months prior to screening.

Subjects  who  had  a  current  diagnosis  of  asthma,  COPD  caused  by  α1-antitrypsin  deficiency,  other significant  respiratory  disorders  (e.g.,  active  tuberculosis,  lung  cancer,  pulmonary  hypertension),  lung resection  within  the  previous  12  months,  or  other  clinically  significant  diseases  in  the  opinion  of  the investigator, were excluded from the study.

## Treatments

Investigational Products and Reference Therapy

Table 4: Study Treatments Supplied for Study CTT116855

| Study Treatment   | Formulation                                                                                                | Strength                                                          | Batch Numbers                                                                                |
|-------------------|------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|----------------------------------------------------------------------------------------------|
| FF/UMEC/VI        | First strip: FF blended with lactose Second strip: UMEC and VI blended with lactose and magnesium stearate | 100 mcg per blister 62.5 mcg and 25 mcg per blister, respectively | R654258, R654259, R682331, R682332, R706369, R706455, R737215, R737216, R750268, and R761665 |

<div style=\"page-break-after: always\"></div>

| FF/VI   | First strip: FF blended with lactose Second strip: VI blended with lactose and magnesium stearate                          | 100 mcg per blister 25 mcg per blister   | R643600, R660895, R660896, R677960, R677977, R692155, R708434, R708435, R744923, R744928, R763259, and R775856   |
|---------|----------------------------------------------------------------------------------------------------------------------------|------------------------------------------|------------------------------------------------------------------------------------------------------------------|
| UMEC/VI | First strip: UMEC blended with lactose and magnesium stearate Second strip: VI blended with lactose and magnesium stearate | 62.5 mcg per blister 25 mcg per blister  | R602192, R661669, R693417, R701920, and R733950                                                                  |

Salbutamol  (rescue  medication)  via  a  metered-dose  inhaler  (MDI)  with  a  spacer  was  issued  for reversibility  testing  at  Screening.    Salbutamol  MDI  or  NEBULES  were  provided  to  the  subjects  at Screening for as-needed use throughout the study.

## Outcomes/endpoints

## Primary Efficacy Endpoint

The primary efficacy endpoint was the annual rate of moderate/severe exacerbations on patients treated with FF/UMEC/VI compared with both FF/VI and UMEC/VI.

The rate of moderate/severe COPD exacerbations is an established clinically relevant endpoint based on known  associations  with  disease  morbidity  and  mortality.  Exacerbations  of  moderate  severity  were defined  as  those  requiring  treatment  with  oral/systemic  corticosteroids  and/or  antibiotics  while  severe exacerbations  were  defined  as  those  requiring  in-patient  hospitalisation  or  resulted  in  death.  Mild exacerbations were defined as those self-managed by the subjects and were not associated with the use of corticosteroids or antibiotics or hospitalisation.

## Secondary Efficacy Endpoints

The secondary efficacy endpoints included:

- Change from Baseline trough FEV1 at Week 52 comparing FF/UMEC/VI with FF/VI
- Change from Baseline SGRQ Total Score at Week 52 comparing FF/UMEC/VI with FF/VI
- Time to first on-treatment moderate/severe exacerbation comparing FF/UMEC/VI with FF/VI and with UMEC/VI
- Annual rate of on-treatment moderate/severe exacerbations comparing  FF/UMEC/VI with UMEC/VI in the subset of subjects with a blood eosinophil count ≥ 150 cells/µL
- Time to first on-treatment moderate/severe exacerbation comparing FF/UMEC/VI with UMEC/VI in the subset of subjects with a blood eosinophil count ≥ 150 cells/µL
- Annual  rate  of  on-treatment  severe  exacerbations  comparing  FF/UMEC/VI  with  FF/VI  and  with UMEC/VI

To further investigate the potential for blood eosinophil levels to predict the exacerbation response to an ICS in COPD, the annual rate of on-treatment moderate/severe exacerbations and the time to first on-

<div style=\"page-break-after: always\"></div>

treatment moderate/severe exacerbation in the subset of subjects with a blood eosinophil count ≥ 150 cells/µl  for  the  comparison  of  FF/UMEC/VI  with  UMEC/VI  (evaluating  the  effect  of  FF)  were  defined  as secondary endpoints.

Trough FEV1 at Week 52 was chosen as a secondary endpoint for evaluation of lung function as it is a robust,  well  established  and  objective  means  of  demonstrating  bronchodilator  efficacy  and  duration  of effect.  Additional  assessments of trough FEV1 were obtained throughout the trial to evaluate response over time.

The  SGRQ  was  selected  as  a  widely-accepted  measure  to  evaluate  change  in  disease-specific  HRQoL. Subjects  completed  the  SGRQ  for  COPD  (SGRQ-C),  a  COPD-specific  version  of  the  SGRQ  designed  to measure the impact of the disease on their HRQoL. The primary analysis of SGRQ Total score was at Week 52 (secondary endpoint). The minimum clinically important difference (MCID) for this instrument of a 4-unit reduction in SGRQ Total Score from baseline was used for the responder analysis. The CAT was used  to  measure  COPD-specific  health  status  with  the  MCID  of  a  &gt;2-unit  improvement  (decrease  in score)  from  baseline  used  for  the  responder  analysis.  Symptom  assessments,  all  defined  as  'other' endpoints included the TDI using the 1 unit TDI score as the accepted MCID for responder analysis and diary assessments of rescue medication use and night-time awakenings. An additional efficacy endpoint of  note  was  all-cause  mortality.  Inclusion  of  this  endpoint  was  considered  appropriate  for  evaluation based on the COPD severity of the patient population under study, the association of exacerbations with mortality, and the large sample size and duration of the study. While all-cause mortality was categorized as an efficacy endpoint to assess potential benefit, this endpoint may also be used as a safety endpoint.

## Safety Assessments for Study CTT116855

In consideration of the classes of medications studied and the co-morbidities associated with COPD, this study  was  also  designed  to  provide  a  full  assessment  of  safety  by  evaluating  adverse  events  (AEs), serious  adverse  events  (SAEs),  adverse  events  of  special  interest  (AESI),  in  particular  CV  events  and pneumonia,  CV  effects  (ECGs,  including  evaluation  of  QTc(F),  and  vital  signs),  and  clinical  laboratory tests.  All deaths and non-fatal serious adverse event reports were adjudicated by an independent Clinical Endpoint  Committee  (CEC)  and  a  pre-specified  Major  Adverse  Cardiac  Event  (MACE)  analysis  was conducted.

## Safety endpoints included:

- Incidence of AEs
- Adjudicated Serious Adverse Reports
- Incidence of pneumonia.
- Incidence of CV events (including MACE and CV AEs of special interest [AESI] group)
- Events in the pneumonia AESI group and moderate/severe exacerbations composite
- Events  in  the  pneumonia  AESI  group  leading  to  hospitalisation  or  prolonged  hospitalisation  or death and severe exacerbations
- Time  to  first  event  in  the  pneumonia  AESI  group  resulting  in  hospitalisation  or  prolonged hospitalisation  or  death,  severe  exacerbation  and  event  in  the  CV  AESI  group  resulting  in hospitalisation or prolonged hospitalisation or death
- ECG measurements
- Vital signs

<div style=\"page-break-after: always\"></div>

- Haematological and clinical chemistry parameters
- Oropharyngeal examinations (abnormalities reported as part of the AEs)
- Incidence of bone fractures

## Statistical Methods/Sample size

In study  CTT116855, sample size calculations were based on the primary endpoint, the annual rate of on treatment moderate/severe exacerbations for the co-primary treatment comparisons of FF/UMEC/VI with FF/VI and with UMEC/VI. A total of 10,000 subjects were needed to provide 90% power to detect a reduction in the annual rate of moderate and severe exacerbations in the FF/UMEC/VI arm compared with the UMEC/VI arm (assuming a true 15% reduction) and a reduction compared with the FF/VI arm (assuming a true 12% reduction). Calculations were based on a negative binomial regression model and used a two-sided 1% significance level.

For  the  analysis,  the  overall  type  I  error  was  controlled  at  α=0.05.  Multiplicity  across  the  co- primary treatment comparisons was accounted for by using the truncated Hochberg procedure with a truncation parameter of γ=0.6.

Additionally, multiplicity was controlled across the key secondary endpoints/treatment comparisons using a hierarchical, closed testing procedure. The secondary hypothesis tests were grouped sequentially in two blocks of two comparisons each (lung function and symptoms, and time to first exacerbation event). Each block of comparisons was also adjusted for multiplicity using the truncated Hochberg method as described for the primary endpoint analysis with a truncation parameter of γ=0.6 for the first block and a truncation parameter of γ=1 for the second block.

The  primary  analysis  of  the  number  of  moderate/severe  COPD  exacerbations  was  performed  using  a generalized linear model assuming the negative binomial distribution. The primary analysis used data for the  ITT  population  collected  while  subjects  were  on  study  treatment.  The  model  included  terms  for treatment  group,  gender,  exacerbation  history  ( ≤ 1, ≥ 2  moderate/severe),  smoking  status  at Screening, baseline disease severity (as post-bronchodilator % predicted FEV1) and geographical region, with the logarithm of time on treatment as an offset variable. A sensitivity analysis was performed where all available data collected until the time of study withdrawal was used. For this sensitivity analysis, the total  number of events and the total time in the study (both on-treatment and off-treatment) prior to study withdrawal were used in the analysis model. Further, several additional sensitivity analyses were performed to evaluate the impact of missing data on the primary analysis of the primary endpoint.

The  secondary  endpoints  of  trough  (pre-dose  in  morning)  FEV1  and  SGRQ  Total  score  were  analysed using mixed model repeated measures (MMRM) with covariates of treatment group, smoking status at Screening, baseline, geographical region, and visit, plus interaction terms for visit by baseline and visit by treatment  group.  The  proportion  of  responders  according  to  SGRQ  Total  Score  was  analysed  using  a generalized linear mixed model with a logit link function, including terms for treatment group, smoking status  (Screening),  geographical  region,  visit,  baseline  SGRQ  Total  Score  and  baseline  by  visit  and treatment group by visit interactions.

The  analysis  of  the  secondary  endpoint  of  time  to  first  moderate/severe  exacerbation  used  Cox ' s proportional  hazards  model,  adjusting  for  treatment  group,  gender,  exacerbation  history  ( ≤ 1, ≥ 2

<div style=\"page-break-after: always\"></div>

moderate/severe),  smoking  status  at  Screening,  baseline  disease  severity  (as  %  post-bronchodilator predicted FEV1) and geographical region.

The secondary endpoint of annual rate of severe exacerbations was analysed in the same way as the primary endpoint.

Rescue use (mean number of occasions per day and percentage of rescue-free days) and mean number of night-time awakenings per night were analysed in a similar way to trough FEV1.

## Populations Analysed

A total of 10,367 subjects were randomised to receive blinded study treatment.  Of these, 12 subjects were randomised in error and recorded as screen failures, leaving 10,355 subjects included in the ITT Population.    Subjects  were  randomised  using  a  2:2:1  ratio  to  the  FF/UMEC/VI  (N=4151),  FF/VI (N=4134), and UMEC/VI (N=2070) groups, respectively.

Figure 2: Subject Disposition (Study CTT116855)

<!-- image -->

1. All subjects who signed informed consent and for whom a record exists on the study database.
2. Percentage was based on the number of subjects who attended the Screening Visit.

<div style=\"page-break-after: always\"></div>

3. All randomised subjects, excluding those randomised in error that did not receive study treatment.
4. ITT subjects who have a baseline eosinophil assessment.
5. ITT subjects who completed a BDI assessment on Day 1.
6. ITT subjects from sites included in the ECG substudy that have a pre-dose ECG assessment at Week 4.
7. A subject was considered to have completed treatment if they did not prematurely discontinue study treatment and attended the Week 52 visit.
8. A subject was considered to have completed the study if they had either attended the Week 52 visit or had a phone contact at Week 52. Subjects could have only one primary reason for study withdrawal. One subject randomised to FF/UMEC/VI completed the study but was reported as prematurely withdrawn in the eCRF in error. This subject is summarised as 'Prematurely withdrawn,' primary reason: Investigator discretion.
9. One subject did not complete the study but reason for non-completion was not entered in the eCRF.

<div style=\"page-break-after: always\"></div>

Table 5: Subject Populations (Study CTT116855, Randomised Subjects)

|                         | Number of Subjects by Region, Country,   | Number (%) of Subjects   | Number (%) of Subjects   | Number (%) of Subjects   | Number (%) of Subjects   |
|-------------------------|------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| Population              | Site                                     | FF/UMEC/VI 100/62.5/25   | FF/VI 100/25             | UMEC/VI 62.5/25          | Total                    |
| Randomised, N           | ---                                      | 4155                     | 4139                     | 2073                     | 10,367                   |
| ITT 1 , N               | RAP Table 1.07                           | 4151                     | 4134                     | 2070                     | 10,355                   |
| Pre-dose ECG 2, 3       | RAP Table 1.08                           | 367 (9)                  | 332 (8)                  | 157 (8)                  | 856 (8)                  |
| TDI3,4                  | RAP Table 1.09                           | 2029 (49)                | 2014 (49)                | 1015 (49)                | 5058 (49)                |
| Eosinophil subgroup 3 n |                                          |                          |                          |                          |                          |
|                         |                                          | 4143                     | 4125                     | 2065                     | 10,333                   |
| <150 cells/µL           |                                          | 1844 (45)                | 1769 (43)                | 869 (42)                 | 4482 (43)                |
| ≥150 cells/µL           |                                          | 2299 (55)                | 2356 (57)                | 1196 (58)                | 5851 (57)                |

## Subject Disposition

A total of 13,906 subjects from 37 countries were enrolled (signed an ICF) in this study.

Of the subjects enrolled, 807 (6%) failed pre-screening and of those who attended the Screening Visit, 2744 (21%) failed screening (Table 5).  Most of the screen failures were due to subjects not meeting the inclusion/exclusion  criteria  (2415  subjects  [18%]).    The  most  frequently  failed  inclusion  criteria  were history of exacerbations (753 subjects [27%]), severity of COPD disease (533 subjects [19%]), and CAT score at Screening (324 subjects [12%]).  The most frequently failed exclusion criteria were unresolved pneumonia  and/or  moderate/severe  COPD  exacerbation  (358  subjects  [13%]),  abnormal  chest  X-ray (133 subjects [5%]), and non-compliance (124 subjects [5%]).  A subject could have only one primary reason  as  determined  by  the  Investigator  for  screen  failure,  but  more  than  one  inclusion/exclusion criterion could have been selected.

A total  of  10,367  subjects  were  randomised,  but  12  were  randomised  in  error  (screen  failures);  thus, 10,355 subjects were included in the ITT Population.  The largest subject participation was from the US (2406  subjects  [23%])  followed  by  Germany  (1187  subjects  [11%]),  Argentina  (972  subjects  [9%]), China (535 subjects [5%]), and Spain (499 subjects [5%]).  The number of subjects included in the ITT Population per study site ranged from 1 to 52.

The majority of subjects completed study treatment (77%) and completed the study (88%).  Of the 23% of  subjects  who  were  prematurely  discontinued  from  study  treatment,  the  most  frequently  reported reasons were AE (7%), decision by subject or proxy (7%), and lack of efficacy (6%).  Of the 12% of subjects  who  were  prematurely  withdrawn from the study, the most frequently reported reasons were withdrawal of consent (6%) and AE (4%).

Overall,  the  percentage  of  subjects  who  prematurely  discontinued  study  treatment  was  lower  in  the FF/UMEC/VI  group  (18%)  than  in  the  FF/VI  (25%)  and  UMEC/VI  (27%)  groups.    The  percentage  of subjects who prematurely discontinued study treatment due to AE or lack of efficacy was lower in the FF/UMEC/VI group (AE: 6%; lack of efficacy: 4%) than in the FF/VI (AE: 8%; lack of efficacy: 8%) and UMEC/VI  (AE:  9%;  lack  of  efficacy:  8%)  groups.    The  time  to  premature  discontinuation  of  study treatment  is  shown  in  Figure  4.    The  percentage  of  subjects  who  prematurely  discontinued  study

<div style=\"page-break-after: always\"></div>

treatment was lower in the FF/UMEC/VI group than in the FF/VI or UMEC/VI groups through the course of the study.

Overall, the percentage of subjects who were prematurely withdrawn from the study was slightly lower in the  FF/UMEC/VI  group  (11%)  than  in  the  FF/VI  (13%)  and  UMEC/VI  (14%)  groups.  The  reasons  for premature  study  withdrawal  were  similar  across  treatment  groups.  The  percentage  of  subjects  who prematurely withdrew from the study was slightly lower in the FF/UMEC/VI group than in the FF/VI or UMEC/VI groups through the course of the study.

Table 6 Subject Disposition (Study CTT116855, ITT Population)

|                                                    | Number (%) of Subjects        | Number (%) of Subjects   | Number (%) of Subjects   | Number (%) of Subjects   |
|----------------------------------------------------|-------------------------------|--------------------------|--------------------------|--------------------------|
| Status                                             | FF/UMEC/VI 100/62.5/25 N=4151 | FF/VI 100/25 N=4134      | UMEC/VI 62.5/25 N=2070   | Total N=10,355           |
| Study Treatment Completion Status                  |                               |                          |                          |                          |
| Completed 1                                        | 3393 (82)                     | 3094 (75)                | 1504 (73)                | 7991 (77)                |
| Prematurely discontinued                           | 758 (18)                      | 1040 (25)                | 566 (27)                 | 2364 (23)                |
| Adverse event                                      | 249 (6)                       | 325 (8)                  | 186 (9)                  | 760 (7)                  |
| Lack of efficacy                                   | 163 (4)                       | 313 (8)                  | 172 (8)                  | 648 (6)                  |
| Protocol deviation                                 | 32 (<1)                       | 41 (<1)                  | 19 (<1)                  | 92 (<1)                  |
| Noncompliance with study treatment                 | 22 (<1)                       | 22 (<1)                  | 12 (<1)                  | 56 (<1)                  |
| Noncompliance with daily diary                     | 11 (<1)                       | 10 (<1)                  | 6 (<1)                   | 27 (<1)                  |
| Subject reached protocol defined stopping criteria | 4 (<1)                        | 1 (<1)                   | 2 (<1)                   | 7 (<1)                   |
| Liver chemistry                                    | 0                             | 0                        | 0                        | 0                        |
| Pregnancy                                          | 0                             | 0                        | 0                        | 0                        |
| QTc                                                | 4 (<1)                        | 1 (<1)                   | 2 (<1)                   | 7 (<1)                   |
| Study closed/terminated                            | 5 (<1)                        | 2 (<1)                   | 5 (<1)                   | 12 (<1)                  |
| Lost to follow-up                                  | 21 (<1)                       | 25 (<1)                  | 14 (<1)                  | 60 (<1)                  |
| Investigator discretion                            | 33 (<1)                       | 36 (<1)                  | 15 (<1)                  | 84 (<1)                  |
| Decision by subject or proxy                       | 250 (6)                       | 296 (7)                  | 153 (7)                  | 699 (7)                  |
| Subject relocated                                  | 31 (<1)                       | 31 (<1)                  | 20 (<1)                  | 82 (<1)                  |
| Frequency of visits                                | 8 (<1)                        | 13 (<1)                  | 6 (<1)                   | 27 (<1)                  |
| Burden of procedures                               | 51 (1)                        | 49 (1)                   | 38 (2)                   | 138 (1)                  |
| Other                                              | 155 (4)                       | 203 (5)                  | 94 (5)                   | 452 (4)                  |
| Unknown 2                                          | 1 (<1)                        | 1 (<1)                   | 0                        | 2 (<1)                   |
| Study Completion Status                            |                               |                          |                          |                          |
| Completed 3                                        | 3714 (89)                     | 3598 (87)                | 1775 (86)                | 9087 (88)                |
| Prematurely withdrawn                              | 437 (11)                      | 536 (13)                 | 295 (14)                 | 1268 (12)                |
| Adverse event                                      | 162 (4)                       | 180 (4)                  | 111 (5)                  | 453 (4)                  |
| Outcome non-fatal                                  | 77 (2)                        | 89 (2)                   | 53 (3)                   | 219 (2)                  |
| Outcome fatal                                      | 85 (2)                        | 91 (2)                   | 58 (3)                   | 234 (2)                  |
| Study closed/terminated                            | 5 (<1)                        | 2 (<1)                   | 4 (<1)                   | 11 (<1)                  |
| Lost to follow-up                                  | 30 (<1)                       | 36 (<1)                  | 22 (1)                   | 88 (<1)                  |
| Investigator discretion                            | 47 (1)                        | 57 (1)                   | 28 (1)                   | 132 (1)                  |
| Withdrew consent                                   | 192 (5)                       | 261 (6)                  | 130 (6)                  | 583 (6)                  |
| Subject relocated                                  | 20 (<1)                       | 27 (<1)                  | 14 (<1)                  | 61 (<1)                  |
| Frequency of visits                                | 9 (<1)                        | 8 (<1)                   | 6 (<1)                   | 23 (<1)                  |
| Burden of procedures                               | 44 (1)                        | 64 (2)                   | 30 (1)                   | 138 (1)                  |
| Other                                              | 123 (3)                       | 177 (4)                  | 86 (4)                   | 386 (4)                  |
| Unknown 4                                          | 1 (<1)                        | 0                        | 0                        | 1 (<1)                   |

<div style=\"page-break-after: always\"></div>

## Demographic and Baseline Characteristics

Based on common enrolment criteria and overlap in participating countries, the populations in Studies CTT116855 and 200812 were similar with respect to demographics and key baseline characteristics of smoking  status,  smoking  history,  severity  of  impairment  in  airflow  obstruction,  reversibility  status, exacerbation history and CAT score. Subjects enrolled in both studies were primarily White, the majority were male, and the average age was 65 to 66 years. Subjects were symptomatic based on a mean CAT score of 19 to 20, had severe airflow obstruction based on a mean percent predicted FEV1 of 41 to 45% and  virtually  all  subjects  experienced  ≥1  moderate  or  severe  exacerbation  in  the  12  months  prior  to screening.

Table 7 Demographic characteristics

|                                                                                                                                                 | CTT116855                            | CTT116855                           | CTT116855                          | 200812                      | 200812                           |
|-------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------|-------------------------------------|------------------------------------|-----------------------------|----------------------------------|
| Demographic/Baseline Characteristic                                                                                                             | FF/UMEC/VI N=4151                    | FF/VI N=4134                        | UMEC/VI N=2070                     | FF/UMEC/VI N=527            | FF/VI + UMEC N=528               |
| Gender: Male, n (%)                                                                                                                             | 2766 (67)                            | 2748 (66)                           | 1356 (66)                          | 391 (74)                    | 394 (75)                         |
| Mean age, yr                                                                                                                                    | 65.3                                 | 65.3                                | 65.2                               | 66.7                        | 65.9                             |
| Race: White 1 , n (%)                                                                                                                           | 3200 (77)                            | 3179 (77)                           | 1604 (77)                          | 416 (79)                    | 416 (79)                         |
| Mean BMI, kg/m                                                                                                                                  | 26.61                                | 26.66                               | 26.58                              | 26.23                       | 26.76                            |
| Current smoker, n (%)                                                                                                                           | 1436 (35)                            | 1423 (34)                           | 728 (35)                           | 209 (40)                    | 192 (36)                         |
| Mean smoking pack-yrs                                                                                                                           | 46.7                                 | 46.4                                | 47.0                               | 43.4                        | 44.2                             |
| GOLD Grade, n (%) 1 ( ≥ 80 %predicted FEV 1 ) 2 ( ≥ 50% to <80 %predicted FEV 1 ) 3 ( ≥ 30% to <50 %predicted FEV 1 ) 4 (<30 %predicted FEV 1 ) | 10 (<1) 1535 (37) 1934 (47) 666 (16) | 8 (<1) 1455 (35) 2031 (49) 639 (15) | 4 (<1) 729 (35) 1017 (49) 319 (15) | 0 174 (34) 251 (49) 90 (17) | 1 (<1) 189 (37) 253 (49) 69 (13) |
| Mean %predicted FEV 2                                                                                                                           | 41.9                                 | 41.6                                | 41.8                               | 44.5                        | 45.5                             |
| Reversible to salbutamol 3 n, (%)                                                                                                               | 734 (18)                             | 810 (20)                            | 366 (18)                           | 73 (14)                     | 74 (14)                          |
| Total Moderate or Severe exacerbations 4 , n                                                                                                    |                                      |                                     |                                    |                             |                                  |
| 0                                                                                                                                               | 2 (<1)                               | 5 (<1)                              | 2 (<1)                             | 0                           | 0                                |
| 1                                                                                                                                               | 1853 (45)                            | 1907 (46)                           | 931 (45)                           | 236 (45)                    | 227 (43)                         |
| ≥ 2                                                                                                                                             | 2296 (55)                            | 2222 (54)                           | 1137 (55)                          | 291 (55)                    | 301 (57)                         |
| Mean CAT Score                                                                                                                                  | 20.1                                 | 20.1                                | 20.2                               | 19.6                        | 20.1                             |

Subjects were required to be on COPD maintenance therapy for at least 3 months prior to study entry and  consistent  with  the  severity  of  the  study  populations  the  majority  of  subjects  were  using  various combinations of COPD  maintenance  therapies. In Study  CTT116855,  the  most  common  COPD maintenance medications reported at entry were ICS + LABA + LAMA (34%), ICS + LABA (26%), LABA + LAMA (8%), and LAMA (7%).  Similar results were obtained in Study 200812.

## Supportive study - Study 200812

Study 200812 was a randomised, double blind, parallel group study comparing FF/UMEC/VI administered in  one  Ellipta  inhaler  with  FF/VI  +  UMEC  administered  in  separate  Ellipta  inhalers  over  24  weeks  in subjects  with  COPD.  This  study  was  designed  to  demonstrate  the  non-inferiority  of  FF/UMEC/VI  to

<div style=\"page-break-after: always\"></div>

FF/VI+UMEC using a primary endpoint of trough FEV1 at Week 24 with a margin of non-inferiority of 50 mL.

Eligible  subjects  were  randomized  (1:1)  to  FF/UMEC/VI  and  placebo  or  FF/VI  and  UMEC  for  24  weeks (N=1055). The randomization was stratified by the number of long-acting bronchodilators received during the Run-in. The total duration of subject participation was approximately 27 weeks, consisting of a 2week  Run-in  period,  24-week  Treatment  Period  and  a  1-week  Safety  Follow-up  Period.  Clinic  visits occurred at Pre-screening/Screening, Randomization (Day1), and after 4, 12, and 24 weeks of treatment. In  addition,  there  was  a  safety  follow-up  telephone  contact  or  clinic  visit  conducted  1  week  after completing the last study visit.

## Study population

To  maintain  consistency  across  patient  populations,  the  enrolment  criteria  were  the  same  as  those described for Study CTT116855. Additionally, consistent with Study CTT116855, subjects must have been receiving daily maintenance treatment for their COPD for at least 3 months prior to screening.

Table 8: Study Treatments Supplied for Study 200812

| Study Treatment         | Formulation                                                                                                | Strength                                            | Batch Numbers    |
|-------------------------|------------------------------------------------------------------------------------------------------------|-----------------------------------------------------|------------------|
| FF/UMEC/VI              | First strip: FF blended with lactose Second strip: UMEC and VI blended with lactose and magnesium stearate | 100 mcg per blister 62.5 mcg and 25 mcg per blister | R762708          |
| Placebo (to match UMEC) | Lactose                                                                                                    | N/A                                                 | R715717, R780908 |
| FF/VI                   | First strip: FF blended with lactose Second strip: VI blended with lactose and magnesium stearate          | 100 mcg per blister 25 mcg per blister              | R763258, R763259 |
| UMEC                    | UMEC blended with lactose and magnesium stearate                                                           | 62.5 mcg per blister                                | R760232          |

Salbutamol  (rescue  medication)  via  a  metered-dose  inhaler  (MDI)  with  a  spacer  was  issued  for reversibility  testing  at  Screening.    Salbutamol  MDI  or  NEBULES  were  provided  to  the  subjects  at Screening for as-needed use throughout the study.

## Outcomes/endpoints

Efficacy endpoints in Study 200812 include:

Primary efficacy endpoint

- Change from baseline in trough FEV1 at Week 24.

## Secondary efficacy endpoints

- Proportion of responders based on the SGRQ total score at Week 24.
- Change from baseline in SGRQ total score at Week 24.
- Proportion of responders based on TDI focal score at Week 24.

<div style=\"page-break-after: always\"></div>

- TDI focal score at Week 24.
- Time to first moderate or severe COPD exacerbation.
- Mean change from baseline in trough FEV1 at the end of Period 1.
- Mean change from baseline in daily AM and PM PEF averaged over Period 1.
- Mean change from baseline in the percentage of symptom-free 24-hour periods during Period 1.
- Mean change from baseline in the percentage of rescue-free 24-hour periods during Period 1.
- Mean change from baseline in ACT score at the end of Period 1.
- Proportion of subjects with ACT score ≥ 20 at the end of Period 1.

The safety endpoints were similar to those in the pivotal trial,

- Incidence of AEs.
- Incidence of AESIs.
- ECG measurements.
- Vital signs.
- Haematological and clinical chemistry parameters.

Overall the choice of efficacy and safety endpoints were appropriate for the population and interventions.

## Statistical Methods/Sample size

The  treatment  comparison  of  primary  interest  was  to  evaluate  the  non-inferiority  of  FF/UMEC/VI  to FF/VI+UMEC for the primary efficacy endpoint of trough FEV1 at Week 24.  No p values for treatment comparisons  were  reported  as  the  primary  objective  of  the  study  was  to  test  the  non-inferiority  of FF/UMEC/VI to FF/VI+UMEC. No inference on non-inferiority or superiority was drawn for the secondary and other efficacy endpoints.

The planned sample size of 816 evaluable subjects provided 90% power to determine non inferiority of FF/UMEC/VI to FF/VI+UMEC based on change from baseline in of trough FEV1 at Week 24, when the margin of non-inferiority was 50 mL and the true mean treatment difference was assumed to be 0 mL. This  used  a  one  sided  2.5%  significance  level  and  an  estimated  residual  standard  deviation  (SD)  for change from baseline in trough FEV1 at Week 24 of 220 mL (based on MMRM analyses of previous Phase IIIa studies in COPD subjects).

It  was  estimated  that  approximately  20%  of  subjects  who  were  randomized  would  either  discontinue study treatment or be excluded from the Modified Per Protocol (mPP) Population at Week 24, therefore approximately 1020 subjects were required to be randomized. The mPP Population comprised all subjects in the ITT Population who did not have a full protocol deviation considered to impact efficacy. Any data following a moderate or severe COPD exacerbation or pneumonia were excluded from mPP analysis due to the potential impact of the exacerbation, pneumonia, or the medications used to treat these events, on the study findings.  Subjects with partial protocol deviations considered to impact efficacy were included in  the  mPP  Population  but  had  their  data  excluded  from  analyses  from  the  time  of  partial  protocol deviation onwards.

The  primary  efficacy  analyses  used  the  mPP  Population.  The  secondary  and  other  efficacy,  and  safety summaries and analyses used the ITT Population.

<div style=\"page-break-after: always\"></div>

The  change  from  baseline  in  trough  FEV1  at  Week  24  was  analysed  using  a  MMRM  analysis  including trough FEV1 recorded at each of Week 4, Week 12, and Week 24.  No imputation was made for any missing numerical data. Covariates included baseline FEV1, stratum (number of long acting bronchodilators used during the Run in period: 0/1 or 2), visit number, geographical region, treatment, visit-by-baseline  interaction,  and  visit-by-treatment  interaction.    Least  squares  means  and  LS  mean change from baseline values for each treatment group with associated standard error (SE) and 95% CIs were calculated.  The estimated treatment difference along with corresponding SE and 95% CI was also calculated. The variance covariance matrix was assumed to be unstructured.  Two models were fitted: one with a response variable of trough FEV1, and one with a response variable of change from baseline in trough FEV1.

The  change  in  SGRQ  total  score  from  baseline  and  the  TDI  focal  score  were  analysed  using  a  MMRM analysis.  No imputation was made for any missing numerical data.  Covariates included baseline SGRQ score or Baseline Dyspnoea Index (BDI) (as applicable), stratum (number of long-acting bronchodilators used  during  the  Run  in  period:  0/1  or  2),  visit  number,  geographical  region,  treatment,  visit-bybaseline/BDI (as applicable) interaction, and visit-by-treatment interaction.  Least squares means and LS mean  change  from  baseline  values  for  each  treatment  group  with  associated  SE  and  95%  CI  were calculated.    The  estimated  treatment  difference  along  with  corresponding  SE  and  95%  CI  was  also calculated.

The  proportion  of  responders  at  Week  24  for  SGRQ  and  TDI  total,  using  cut-off  as  defined  for  Study 200812 was analysed using a generalized linear mixed model including data at Week 12 and Week 24. Covariates included baseline SGRQ score or BDI (as applicable), treatment group, stratum (number of long acting bronchodilators used during the Run in period: 0/1 or 2), geographical region, visit number, visit by baseline/BDI (as applicable) interaction, and visit-by-treatment interaction.

Time  to  first  moderate  or  severe  COPD  exacerbation  was  analysed  using  Cox's  proportional  hazards model.  Covariates included treatment group, gender, exacerbation history (0 to 1, or ≥2 moderate or severe exacerbations within 12 months prior to Screening), stratum (number of long acting bronchodilators used during the Run in period: 0/1 or 2), geographical region, and baseline FEV1 (percent predicted normal).

## Populations Analysed

In study 200812, a total of 1055 subjects were randomized to receive blinded study treatment.

Table 9: Subject Populations (ASE Population, Study 200812)

|                    | Number of subjects, n (%) 1   | Number of subjects, n (%) 1   | Number of subjects, n (%) 1   |
|--------------------|-------------------------------|-------------------------------|-------------------------------|
| Population         | FF/UMEC/VI                    | FF/VI+UMEC                    | Total                         |
| ASE Population, N  |                               |                               | 1311                          |
| Randomized, N      | 527                           | 528                           | 1055                          |
| ITT Population mPP | 527(100)                      | 528 (100)                     | 1055 (100)                    |
| Population         | 478 (91)                      | 478 (91)                      | 956 (91)                      |

## Subject Disposition

<div style=\"page-break-after: always\"></div>

A total of 1311 subjects over 12 countries were pre-screened and 1278 subjects were screened.  There were 33 pre-screen failures, 175 screen failures, and 48 Run-in failures.  A total of 1055 subjects were randomized and received study treatment and 94% of subjects completed the study.

## · Results for both studies CTT116855 and 200812

## Efficacy results

Efficacy results will be presented for the pivotal trial in the first instance, but where endpoints were common across both clinical studies these results will be presented in tandem.

## a) Pivotal Study - CTT116855

## Primary endpoint: Annual Rate of On-Treatment Moderate/Severe Exacerbations

Study CTT116855 used well established criteria to define COPD exacerbations, consistent with regulatory authority guidance on COPD drug development. The diagnosis of an exacerbation was made and recorded by the investigator after contact with the subject. Symptoms of COPD were recorded daily by subjects using  an  eDiary  and  specific  criteria  for  worsening  symptoms  were  used  to  trigger  contact  with  the investigator.  The  symptoms  and  criteria  were  consistent  with  those  used  in  previous  exacerbations studies for the salmeterol/fluticasone propionate combination product and FF/VI.

The  results  for  the  primary  analysis  of  the  primary  endpoint  of  the  annual  rate  of  on-treatment moderate/severe  exacerbations  of  COPD  in  Study  CTT116855  are  summarized  below.    FF/UMEC/VI demonstrated  a  statistically  significant  reduction  in  the  annual  rate  of  on-treatment  moderate/severe exacerbations compared with FF/VI and UMEC/VI (p&lt;0.001 for both comparisons).

Table 10: Analysis of On-Treatment Moderate/Severe COPD Exacerbations Using Negative Binomial Model (CTT116855, ITT Population)

|                                                          | FF/UMEC/VI N=4151   | FF/VI N=4134    | UMEC/VI N=2070   |
|----------------------------------------------------------|---------------------|-----------------|------------------|
| Number subjects Model estimated exacerbation rate 95% CI | 4145 0.91           | 4133 1.07 1.12) | 2069 1.21        |
|                                                          | (0.87, 0.95)        | (1.02,          | (1.14, 1.29)     |
| FF/UMEC/VI vs Column                                     |                     |                 |                  |
| Rate ratio                                               |                     | 0.85            | 0.75             |
| 95% CI                                                   |                     | (0.80, 0.90)    | (0.70, 0.81)     |
| p-value                                                  |                     | <0.001          | <0.001           |
| Percentage reduction in rate                             |                     | 15%             | 25%              |
| 95% CI                                                   |                     | (10%, 20%)      | (19%, 30%)       |

The  supportive  analysis  of  the  annual  rate  of  on-treatment  moderate/severe  exacerbations  using  the Poisson  regression  model  and  sensitivity  analyses  investigating  the  impact  of  missing  data,  which included  analyses  using  both  on-  and  off-treatment  data,  using  on-treatment  data  and  the  Jump  to Reference (J2R) assumption for missing data following treatment discontinuation, and using on- and offtreatment data and the J2R assumption for missing data following study withdrawal were supportive of the findings for the primary analysis for the comparisons of FF/UMEC/VI with FF/VI and UMEC/VI.

<div style=\"page-break-after: always\"></div>

Figure 3: Forest Plot of Adjusted On-treatment Moderate/Severe COPD Exacerbation Rate Ratios and Associated Sensitivity Analyses (CTT116855)

<!-- image -->

The effect  of  FF/UMEC/VI  on  the  annual  rate  of  moderate/severe  COPD  exacerbations  was  maintained when  both  on-  and  off-treatment  data  were  included  in  the  analysis.  For  this  analysis,  FF/UMEC/VI demonstrated a statistically significant reduction in the annual rate of moderate/severe  COPD exacerbations compared with FF/VI (11% reduction, p&lt;0.001) and UMEC/VI (20% reduction, p&lt;0.001).

## Annual Rate of On-Treatment Severe Exacerbations

FF/UMEC/VI demonstrated a statistically significant reduction in the annual rate of on-treatment severe exacerbations  (i.e., resulting  in  hospitalisation/prolonged  hospitalisation  or  death)  compared  with UMEC/VI (p&lt;0.001). The reduction in the annual rate of on-treatment  severe  COPD  exacerbations  for FF/UMEC/VI compared with FF/VI was not statistically significant.

Table 11: Analysis of On-treatment Severe COPD Exacerbations Using Negative Binomial Model (CTT116855, ITT Population)

|                                   | FF/UMEC/VI N=4151   | FF/VI N=4134   | UMEC/VI N=2070   |
|-----------------------------------|---------------------|----------------|------------------|
| Number subjects                   | 4145                | 4133           | 2069 0.19        |
| Model estimated exacerbation rate | 0.13                | 0.15           |                  |
| 95% CI                            | (0.12, 0.14)        | (0.13, 0.16)   | (0.17, 0.22)     |
| FF/UMEC/VI vs Column              |                     |                |                  |
| Rate ratio                        |                     | 0.87           | 0.66             |
| 95% CI                            |                     | (0.76, 1.01)   | (0.56, 0.78)     |
| p-value                           |                     | 0.064          | <0.001           |
| Percentage reduction in rate      |                     | 13%            | 34%              |
| 95% CI                            |                     | (-1%, 24%)     | (22%, 44%)       |

## Time to First Moderate or Severe COPD Exacerbation

As this endpoint was studied in both clinical trials, results from both trials will be summarised here.

## CTT116855

<div style=\"page-break-after: always\"></div>

FF/UMEC/VI  demonstrated a statistically significant decreased risk of a moderate/severe  COPD exacerbation compared with FF/VI and UMEC/VI (p&lt;0.001 for both comparisons)

Table 12: Time to First On-treatment Moderate/Severe COPD Exacerbation (Study CTT116855, ITT Population)

|                                                                                                                                                                                   | FF/UMEC/VI N=4151        | FF/VI N=4134                            | UMEC/VI N=2070                        |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|-----------------------------------------|---------------------------------------|
| Number subjects with event (%) Number of subjects without an event (censored) (%) Probability of having event (%) 95% CI First quartile time to onset (days) FF/UMEC/VI vs Column | 1959 (47) 2192 (53) 49.9 | 2039 (49) 2095 (51) 53.7 (52.1,55.4) 81 | 1036 (50) 1034 (50) 53.3 (51.0, 55.6) |
| Hazard ratio                                                                                                                                                                      |                          |                                         |                                       |
|                                                                                                                                                                                   | (48.3, 51.5)             |                                         |                                       |
|                                                                                                                                                                                   | 112                      |                                         | 73                                    |
|                                                                                                                                                                                   |                          | 0.85                                    | 0.84                                  |
| 95% CI                                                                                                                                                                            |                          | (0.80, 0.91)                            | (0.78, 0.91)                          |
| Percentage reduction in risk                                                                                                                                                      |                          | 14.8%                                   | 16.0%                                 |
| 95% CI                                                                                                                                                                            |                          | (9.3%, 19.9%)                           | (9.4%, 22.1%)                         |
| p-value                                                                                                                                                                           |                          | <0.001                                  | <0.001                                |

Figure 4: Kaplan-Meier Plot of Time to First On-treatment Moderate/Severe COPD Exacerbation (Study CTT116855, ITT Population)

<!-- image -->

Similar results were obtained when both on- and off-treatment data were included in the analysis of time to first moderate/severe exacerbation with risk reductions of 12.8% for FF/UMEC/VI compared with FF/VI and 14.5% for FF/UMEC/VI compared with UMEC/VI (p&lt;0.001 for both comparisons).

## 200812

A  similar  number  of  subjects  reported  an  on  treatment  moderate/severe  COPD  exacerbation  in  the FF/UMEC/VI and FF/VI+UMEC treatment groups (24% and 27%, respectively) with a similar risk of an exacerbation event based on time to first analysis.

<div style=\"page-break-after: always\"></div>

Table 13: Time to First On-Treatment Moderate/Severe COPD Exacerbation (ITT Population, Study 200812)

|                                                    | FF/UMEC/VI (N=527)   | FF/VI+UMEC (N=528)   |
|----------------------------------------------------|----------------------|----------------------|
| Number subjects with event (%)                     | 129 (24)             | 142 (27)             |
| Number of subjects without an event (censored) (%) | 398 (76)             | 386 (73)             |
| Probability of having event (%)                    | 25.2                 | 26.8                 |
| 95% CI                                             | (21.6, 29.2)         | (23.2, 30.8)         |
| First quartile time to onset, days                 | 166.0                | 150.0                |
| FF/UMEC/VI vs FF/VI+UMEC                           |                      |                      |
| Hazard ratio                                       | 0.87                 |                      |
| 95% CI                                             | (0.68, 1.12)         |                      |

Figure 5: Kaplan-Meier Plot of Time to First On-Treatment Moderate/Severe COPD Exacerbation (ITT Population, Study 200812)

<!-- image -->

## Lung Function

## CTT116855

At  Week  52,  a  statistically  significant  improvement  in  trough  FEV1  was  observed  for  FF/UMEC/VI compared with FF/VI (treatment difference: 97 mL; 95% CI: 85 mL, 109 mL; p&lt;0.001) and compared with UMEC/VI (treatment difference: 54 mL; 95% CI: 39 mL, 69 mL; p&lt;0.001).

Table 14: Analysis of LS Mean Change from Baseline in Trough FEV1 (L) at Week 52 for FF/UMEC/VI versus FF/VI or UMEC/VI (Study CTT116855, ITT Population)

| Number subjects with analysable data at Week 52 LS Mean (SE) 95% CI LS Mean Change from baseline (SE) 95% CI   | FF/UMEC/VI 100/62.5/25 N=4151 3366 1.274 (0.0042) (1.265, 1.282) 0.094 (0.0042) (0.086, 0.102)   | FF/VI 100/25 N=4134 3060 1.177 (0.0044) (1.168, 1.185) -0.003 (0.0044) (-0.012, 0.006)   | UMEC/VI 62.5/25 N=2070 1490 1.220 (0.0063) (1.208, 1.232) 0.040 (0.0063) (0.028, 0.052)   |
|----------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|
| FF/UMEC/VI vs Column                                                                                           |                                                                                                  |                                                                                          |                                                                                           |
| Difference (SE)                                                                                                |                                                                                                  | 0.097 (0.0061)                                                                           | 0.054 (0.0076)                                                                            |
| 95% CI                                                                                                         |                                                                                                  | (0.085, 0.109)                                                                           | (0.039, 0.069)                                                                            |
| p-value                                                                                                        |                                                                                                  |                                                                                          |                                                                                           |
| Unadjusted                                                                                                     |                                                                                                  |                                                                                          |                                                                                           |
| Adjusted p-value 1                                                                                             |                                                                                                  | <0.001 <0.001                                                                            | <0.001                                                                                    |

<div style=\"page-break-after: always\"></div>

Improvements in trough FEV1 observed for FF/UMEC/VI compared with FF/VI and UMEC/VI at the first time point assessed (Week 4) were maintained at all subsequent visits (all p&lt;0.001).

Figure 6: Least-squares Mean (95% CI) Change from Baseline in Trough FEV1 (L) (Study CTT116855, ITT Population)

<!-- image -->

## Heath-Related Quality of Life

## CTT116855

FF/UMEC/VI  demonstrated  a  clinically  meaningful  improvement  in  SGRQ  Total  Score  with  a  LS  mean change from baseline of -5.5 units at Week 52 (compared with the MCID of 4 units) and a statistically significant difference compared with FF/VI (between group difference of -1.8 units; 95% CI: -2.4, -1.1; p&lt;0.001)  and  compared  with  UMEC/VI  (between  group  difference  of  -1.8  units;  95%  CI:    2.6,  1.0; p&lt;0.001). Additionally, the odds of being an SGRQ responder versus a non-responder at Week 52 were statistically significantly higher for FF/UMEC/VI compared with FF/VI and UMEC/VI (p&lt;0.001), indicative of clinically meaningful improvements in HRQoL with FF/UMEC/VI over the dual combinations.

<div style=\"page-break-after: always\"></div>

Table 15: Total Score and Responder Analysis at Week 52 (Study CTT116855, ITT Population)

|                                          | FF/UMEC/VI N=4151   | FF/VI N=4134     | UMEC/VI N=2070   |
|------------------------------------------|---------------------|------------------|------------------|
| SGRQ Total Score                         |                     |                  |                  |
| n with analysable data at Week 52        | 3318                | 3026 46.8 (0.24) | 1470 46.8        |
| LS mean (SE)                             | 45.0 (0.23)         |                  | (0.35)           |
| LS mean change from Baseline (SE)        | -5.5 (0.23)         | -3.7 (0.24)      | -3.7 (0.35)      |
| FF/UMEC/VI vs Column                     |                     |                  |                  |
| Difference (SE)                          |                     | -1.8 (0.34)      | -1.8 (0.42)      |
| 95% CI                                   |                     | (-2.4, -1.1)     | (-2.6, -1.0)     |
| p-value                                  |                     | <0.001           | <0.001           |
| Responders According to SGRQ Total Score |                     |                  |                  |
| n                                        | 4108                | 4092             | 2050             |
| Responder 1 , n (%)                      | 1723 (42)           | 1390 (34)        | 696 (34)         |
| Non-responder, n (%)                     | 2385 (58)           | 2702 (66)        | 1354 (66)        |
| FF/UMEC/VI vs Column                     |                     |                  |                  |
| Odds ratio                               |                     | 1.41             | 1.41             |
| 95% CI                                   |                     | (1.29, 1.55)     | (1.26, 1.57)     |
| p-value                                  |                     | <0.001           | <0.001           |

## 200812

Both  treatments  demonstrated  similar  clinically  meaningful  improvements  in  HRQoL  as  measured  by change  from  baseline  SGRQ  Total  Score  at  Week  24  with  a  similar  proportion  of  subjects  defined  as responders by SGRQ Total Score.

Table 16: SGRQ Total Score and Responder Analysis at Week 24 (Study 200812, ITT Population)

|                                | FF/UMEC/VI (N=527)   | FF/VI+UMEC (N=528)   |
|--------------------------------|----------------------|----------------------|
| SGRQ Total Score               |                      |                      |
| n (Analyzable Data at Week 24) | 489                  | 483 -4.935           |
| LS Mean Change (SE)            | -5.841 (0.5870)      | (0.5904)             |
| 95% CI                         | (-6.993, -4.689)     | (-6.094, -3.777)     |
| FF/UMEC/VI vs FF/VI+UMEC       |                      |                      |
| n                              | 489                  | 483                  |
| Responder 1 , n (%)            | 243 (50)             | 247 (51)             |
| Non-Responder, n (%)           | 246 (50)             | 236 (49)             |
| FF/UMEC/VI vs FF/VI+UMEC       |                      |                      |
| Odds Ratio                     | 0.92                 | 0.92                 |
| 95% CI                         | (0.71, 1.20)         | (0.71, 1.20)         |

## TDI Focal Score

In  both  studies,  the  self-administered  computerised  versions  of  the  TDI  and  BDI  questionnaires  were used.

## CTT116855

All analyses presented for this study are based on the TDI Population which comprised of 5058 subjects at selected sites who completed a pre-dose BDI assessment at Day 1.

At  Week  52,  FF/UMEC/VI  demonstrated  a  statistically  significant  improvement  in  TDI  focal  score compared with FF/VI (p=0.020).  The treatment difference for FF/UMEC/VI compared with UMEC/VI at Week 52 did not meet statistical significance. The odds of being a TDI responder versus non-responder at Week 52 were statistically significantly higher for FF/UMEC/VI compared with FF/VI and UMEC/VI.

<div style=\"page-break-after: always\"></div>

Table 17: TDI Focal Score and Responder Analysis at Week 52 (Study CTT116855, TDI Population)

|                                         | FF/UMEC/VI N=2029   | FF/VI N=2014   | UMEC/VI N=1015   |
|-----------------------------------------|---------------------|----------------|------------------|
| TDI Focal Score                         |                     |                |                  |
| n analysable data                       | 1959                | 1861           | 930              |
| n with analysable data at Week 52       | 1549                | 1392           | 670              |
| LS mean (SE)                            | 0.98 (0.079)        | 0.71 (0.083)   | 0.89 (0.120)     |
| 95% CI                                  | (0.82, 1.13)        | (0.55, 0.87)   | (0.65, 1.12)     |
| FF/UMEC/VI vs Column                    |                     |                |                  |
| Difference (SE)                         |                     | 0.27 (0.115)   | 0.09 (0.144)     |
| 95% CI                                  |                     | (0.04, 0.49)   | (-0.19, 0.37)    |
| p-value                                 |                     | 0.020          | 0.522            |
| Responders According to TDI Focal Score |                     |                |                  |
| n                                       | 2029                | 2014           | 1015             |
| Responder 1 , n (%)                     | 730 (36)            | 591 (29)       | 302 (30)         |
| Non-responder, n(%)                     | 1299 (64)           | 1423 (71)      | 713 (70)         |
| FF/UMEC/VI vs Column                    |                     |                |                  |
| Odds ratio                              |                     | 1.36           | 1.33             |
| 95% CI                                  |                     | (1.19, 1.55)   | (1.13, 1.57)     |
| p-value                                 |                     | <0.001         | <0.001           |

## Study 200812

Findings for the TDI focal score indicated similar benefit of FF/UMEC/VI and FF/VI + UMEC to improve dyspnoea  at  Week  24.  Both  treatments  resulted  in  clinically  meaningful  improvement  in  dyspnoea  as measured by TDI at Week 24 based on TDI focal scores of ≥1. TDI focal scores and the odds of being a TDI responder versus non-responder were similar between groups at Week 24.

Table 18: TDI Focal Score and Responder Analysis at Week 24 (Study 200812, ITT Population)

|                                | FF/UMEC/VI (N=527)   | FF/VI+UMEC (N=528)   |
|--------------------------------|----------------------|----------------------|
| TDI Focal Score                |                      |                      |
| n (Analyzable Data at Week 24) | 482                  | 481                  |
| LS Mean Change (SE)            | 2.029 (0.1252)       | 1.892 (0.1254)       |
| 95% CI                         | (1.784, 2.275)       | (1.646, 2.138)       |
| FF/UMEC/VI vs FF/VI+UMEC       |                      |                      |
| n (Analyzable Data at Week 24) | 482                  | 481                  |
| Responder 1 , n (%)            | 268 (56)             | 271 (56)             |
| Non-Responder, n (%)           | 214 (44)             | 210 (44)             |
| FF/UMEC/VI vs FF/VI+UMEC       |                      |                      |
| Odds Ratio                     | 0.95                 | 0.95                 |
| 95% CI                         | (0.72, 1.25)         | (0.72, 1.25)         |

## Rescue Medication Use

Rescue medication use was evaluated in Study CTT116855 only.

Across  treatment  groups,  there  was  a  slight  trend  for  increased  use  of  rescue  medication  over  time, although this was less apparent in the FF/UMEC/VI treatment group.

<div style=\"page-break-after: always\"></div>

Figure 7: Least-squares Mean (95% CI) Change from Baseline Mean Number of Occasions of Rescue Use per Day by 4-Weekly Periods (Study CTT16855, ITT Population)

<!-- image -->

Over Weeks 49 to 52, there was a statistically significant lower mean change in number of occasions of rescue  medication  use  per  day  in  the  FF/UMEC/VI  compared  with  FF/VI  and  UMEC/VI  (p&lt;0.001). Similarly, the change in the percentage of rescue free days, reflecting increase use across groups, was smaller with FF/UMEC/VI compared with FF/VI and UMEC/VI (p&lt;0.001).

Table 19: Rescue Medication Use over Weeks 49 to 52 (Study CTT116855, ITT Population)

|                                                           | FF/UMEC/VI N=4151                                         | FF/VI N=4134                                                   | UMEC/VI N=2070                                            |
|-----------------------------------------------------------|-----------------------------------------------------------|----------------------------------------------------------------|-----------------------------------------------------------|
| Mean Number of Occasions of Rescue Medication Use per Day | Mean Number of Occasions of Rescue Medication Use per Day | Mean Number of Occasions of Rescue Medication Use per Day      | Mean Number of Occasions of Rescue Medication Use per Day |
| Number subjects with analysable data                      | 3322 1.75 (0.031) (1.69, 1.81)                            | 3002 2.03 (0.032) (1.97, 2.09) 0.44 (0.032) (0.38, 0.50) -0.28 | 1462 2.05 (0.045) (1.96, 2.14) 0.46 (0.045) (0.37, 0.55)  |
| LS Mean (SE)                                              |                                                           |                                                                |                                                           |
| 95% CI                                                    |                                                           |                                                                |                                                           |
| LS Mean Change (SE)                                       | 0.16 (0.031)                                              |                                                                |                                                           |
| 95% CI                                                    | (0.10, 0.22)                                              |                                                                |                                                           |
| FF/UMEC/VI vs Column                                      |                                                           |                                                                |                                                           |
| Difference (SE)                                           |                                                           | (0.044)                                                        | -0.30 (0.055)                                             |
| 95% CI                                                    |                                                           | (-0.37, -0.19)                                                 | (-0.41, -0.19)                                            |
| p-value                                                   |                                                           | <0.001                                                         | <0.001                                                    |
| Percentage of Rescue-free Days                            | Percentage of Rescue-free Days                            | Percentage of Rescue-free Days                                 | Percentage of Rescue-free Days                            |
| Number subjects with analysable data                      | 3322                                                      | 3002                                                           | 1462                                                      |
| LS Mean (SE)                                              | 42.5 (0.61)                                               | 37.3 (0.62)                                                    | 38.1 (0.89)                                               |
| 95% CI                                                    | (41.4, 43.7)                                              | (36.1, 38.6)                                                   | (36.4, 39.9)                                              |
| LS Mean Change (SE)                                       | -1.9 (0.61)                                               | -7.1 (0.62)                                                    | -6.3 (0.89)                                               |
| 95% CI                                                    | (-3.1, -0.7)                                              | (-8.3, -5.9)                                                   | (-8.0, -4.6)                                              |

## Night-time Awakenings

Night-time awakenings were evaluated in Study CTT116855 only.

Over  Weeks  49  to  52,  FF/UMEC/VI  demonstrated  a  statistically  significant  reduction  in  in  the  mean number  of  night-time  awakenings  per  night  compared  with  FF/VI  and  compared  with  UMEC/VI  (p ≤0.005)

<div style=\"page-break-after: always\"></div>

Table 20: Analysis of Night-time Awakenings Due to COPD over Weeks 49 to 52 for FF/UMEC/VI versus FF/VI or UMEC/VI (Study CTT116855, ITT Population)

| Night-time Awakenings per Night Due to COPD (Weeks 49 to 52)                          | FF/UMEC/VI N=4151                                           | FF/VI N=4134                                                              | UMEC/VI N=2070                                                            |
|---------------------------------------------------------------------------------------|-------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|
| n LS Mean (SE) 95% CI LS Mean Change (SE) 95% CI FF/UMEC/VI vs Column Difference (SE) | 3322 0.48 (0.012) (0.46, 0.51) -0.21 (0.012) (-0.24, -0.19) | 3002 0.53 (0.013) (0.51, 0.56) -0.16 (0.013) (-0.19, -0.14) -0.05 (0.018) | 1462 0.58 (0.018) (0.54, 0.61) -0.12 (0.018) (-0.15, -0.08) -0.10 (0.022) |

## All-Cause Mortality

This endpoint was evaluated in Study CTT116855 only.

The analysis for on-treatment all-cause mortality included deaths that occurred up to 7 days after the last  day  of  treatment  and  was  based  on  the  actual  date  of  death.    Twenty  three  percent  of  subjects prematurely discontinued study treatment prior to Week 52. The incidence of on treatment deaths was low  across  groups  with  1.20%  for  FF/UMEC/VI,  1.19%  for  FF/VI,  and  1.88%  for  UMEC/VI.  The  most common  primary  causes  of  death  across  treatment  groups  were  CV  (including  sudden  death)  and respiratory  (all  &lt;1%  across  groups).  Death  was  adjudicated  as  associated  with  COPD  for  18  of  50 subjects in the FF/UMEC/VI group, 14 of 49 subjects in the FF/VI group, and 15 of 39 subjects in the UMEC/VI group.

The FF/UMEC/VI group demonstrated a statistically significant reduction in the risk of on-treatment allcause  mortality  compared  with  the  UMEC/VI  group  (HR:  0.58;  95%  CI:  0.38,  0.88;  p=0.011, corresponding to a risk reduction of 42.1%). For the comparison of FF/UMEC/VI and FF/VI, the risk of on treatment all-cause mortality was similar (HR: 0.95; 95% CI: 0.64, 1.40, p=0.780, corresponding to a risk reduction of 5.5%).

<div style=\"page-break-after: always\"></div>

Table 21: Kaplan-Meier Plot of On-treatment Time to All-cause Mortality (Study CTT116855, ITT Population)

<!-- image -->

Off-treatment data for all-cause mortality included data collected from subjects after discontinuation of study  treatment  whether  or  not  they  remained  in  the  study.    When  on  and  off-treatment  data  were included in the analysis, vital status was available for 9781 subjects (94%) of the study population at Week 52.

When  both  on-and  off  treatment  mortality  data  were  included  in  the  analysis,  the  significant  risk reduction  in  all-cause  mortality  was  maintained  for  FF/UMEC/VI  compared  with  UMEC/VI,  indicating  a robustness  of  treatment  effect.  Specifically,  FF/UMEC/VI  significantly  reduced  the  risk  of  on-  and  offtreatment  all-cause  mortality  compared  with  UMEC/VI  (HR  0.71;  95%  CI:  0.51,  0.99;  p=0.043, corresponding to a risk reduction of 28.6%). The risk of all-cause mortality was similar for FF/UMEC/VI compared with FF/VI (HR: 0.90, 95% CI: 0.67, 1.20; p=0.458).

## Efficacy in Subgroups

Subgroup analyses were performed for Study CTT116855 only.

For Study CTT116855, an assessment was performed for the ITT Population to determine whether the effect  of  treatment  on  the  primary  endpoint  was  modified  by  the  different  levels  of  the  following subgroups:  gender, age group, race, geographical region, exacerbation history, and CV risk.

No  significant  interactions  of  treatment  with  gender,  race,  geographical  region,  or  number  of  CV  risk factors  were  observed  on  the  primary  endpoint.  A  significant  subgroup-by-treatment  interaction  was observed for exacerbation history (p=0.010) and age group (p=0.052).

Further investigation of the significant interaction of treatment with age showed that the point estimate for the HR favoured FF/UMEC/VI over both FF/VI and UMEC/VI for each age category.  The significant interaction is likely due to a difference in the magnitude of the rate ratio, which was greater in the 65 to 74 year age category and lower in the ≤64 year category for both treatment comparisons.

Relative to the comparison of FF/UMEC/VI with FF/VI in the overall ITT Population, there were no clinically relevant  differences  in  the  annual  rate  of  moderate/severe  exacerbations  in  any  subgroup  categories

<div style=\"page-break-after: always\"></div>

(Figure  8).    All  point  estimates  of  the  rate  ratio  favoured  FF/UMEC/VI  with  some  variation  in  the magnitude of rate reduction.

For the subgroups of gender and number of CV risk factors, point estimates for the FF/UMEC/VI versus FF/VI rate ratio were all contained within the 95% CI of the comparison within the overall ITT Population. At  least  one  of  the  point  estimates  for  a  category  within  the  race,  geographical  region,  exacerbation history, and age subgroups fell outside the 95% CI of the comparison within the overall ITT Population (Figure  8).    These  results  tended  to  occur  in  smaller  subgroup  categories  and  were  not  considered clinically relevant due to overlapping 95% CI with other categories within the respective subgroup.

Figure 8: Forest Plot of On-treatment Moderate/Severe Exacerbation Rate Ratio Overall and by Subgroup - FF/UMEC/VI vs FF/VI (Study CTT116855, ITT Population)

<!-- image -->

Relative  to  the  comparison  of  FF/UMEC/VI  with  UMEC/VI  in  the  overall  ITT  Population,  there  were  no clinically  relevant  differences  in  the  annual  rate  of  moderate/severe  exacerbations  in  any  subgroup category.    All  point  estimates  of  the  rate  ratio  for  these  subgroups  favoured  FF/UMEC/VI  with  some variation in the magnitude of rate reduction, apart from the comparison in the 'Other' race category.

For the subgroups of gender, exacerbation history, and number of CV risk factors, point estimates for the FF/UMEC/VI versus UMEC/VI rate ratio were all contained within the 95% CI of the comparison within the overall  ITT  Population.    At  least  one  of  the  point  estimates  for  a  category  within  the  age,  race,  and geographical  region  subgroups  fell  outside  the  95%  CI  of  the  comparison  within  the  overall  ITT Population.    These  results  tended  to  occur  in  smaller  subgroup  categories  and  were  not  considered clinically relevant due to overlapping 95% CI with other categories within the respective subgroup.

Figure 9: Forest Plot of On-treatment Moderate/Severe Exacerbation Rate Ratio Overall and by Subgroup - FF/UMEC/VI vs UMEC/VI (Study CTT116855, ITT Population)

<div style=\"page-break-after: always\"></div>

<!-- image -->

## COPD Exacerbations by Eosinophil Subgroup

In CTT116855, the two secondary endpoints of model-estimated annual rate of on-treatment moderate/severe exacerbations and time to first on-treatment moderate/severe exacerbation, evaluated efficacy in the subgroup of subjects in the ITT Population with a baseline blood eosinophil count of ≥ 150 cells/µL.    For  these  two  endpoints,  the  key  comparison  was  between  the  FF/UMEC/VI  and  UMEC/VI groups,  although  the  FF/UMEC/VI  and  FF/VI  groups  were  also  compared,  and  treatment  comparisons were also made in the subgroup of subjects with a baseline blood eosinophil count of &lt;150 cells/µL.

## Annual Rate of On-treatment Moderate/Severe Exacerbations by Eosinophil Subgroup

Regardless  of  baseline  blood  eosinophil  count  subgroup,  treatment  with  FF/UMEC/VI  resulted  in  a statistically  significant  reduction  in  the  model-estimated  annual  rate  of  on  treatment  moderate/severe exacerbations  at  Week  52  compared  with  FF/VI  (both  p≤0.003)  and  compared  with  UMEC/VI  (both p≤0.034).    For  the  comparison  between  FF/UMEC/VI  and  FF/VI,  the  magnitude  of  the  reduction  was greater  for  the  subgroup  of  subjects  with  baseline  blood  eosinophil  count  of  &lt;150  cells/µL  (rate reduction: 20%; rate ratio: 0.80; 95% CI: 0.73, 0.88; p&lt;0.001) than in the subgroup of subjects with baseline blood eosinophil count of ≥ 150 cells/µL (rate reduction: 12%; rate ratio: 0.88; 95% CI: 0.81, 0.96; p=0.003).  For the comparison between FF/UMEC/VI and UMEC/VI, the magnitude of the reduction was  greater  for  the  subgroup  of  subjects  with  baseline  blood  eosinophil  count  of ≥ 150  cells/µL  (rate reduction: 32%; rate ratio: 0.68; 95% CI: 0.62, 0.75; p&lt;0.001) than in the subgroup of subjects with baseline blood eosinophil count of &lt;150 cells/µL (rate reduction: 12%; rate ratio: 0.88; 95% CI: 0.78, 0.99; p=0.034).

<div style=\"page-break-after: always\"></div>

## Time to First Moderate/Severe Exacerbation by Eosinophil Subgroup

Based  on  the  time  to  first  analysis,  treatment  with  FF/UMEC/VI  in  subjects  with  a  baseline  blood eosinophil  count  of ≥ 150  cells/µL  resulted  in  a  statistically  significant  reduction  in  the  risk  of  a moderate/severe  exacerbation  by  15.0%  compared  with  FF/VI  (HR:  0.85;  95%  CI:  7.8%,  21.7%; p&lt;0.001)  and  by  23.2%  compared  with  UMEC/VI  (HR:  0.77;  95%  CI:  15.4%,  30.4%;  p&lt;0.001).  In subjects with a baseline blood eosinophil count of &lt;150 cells/µL, treatment with FF/UMEC/VI resulted in a statistically significant reduction in the risk of a moderate/severe exacerbation by 14.6% compared with FF/VI (HR: 0.85; 95% CI: 6.1%, 22.3%; p&lt;0.001). The reduction in risk compared with UMEC/VI was not statistically significant (4.0%; HR: 0.96; 95% CI: -8.2%, 14.8%; p=0.503).

## Summary of main study (CTT116855)

The  following  table  summarise  the  efficacy  results  from  the  main  studies  supporting  the  present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

## Table 22 Summary of main study

| Title: A phase III, 52 weeks, randomised, double-blind, 3-arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF/UMEC/VI with the fixed dose dual combinations of FF/VI and UMEC/VI, all administered once-daily in the morning via a dry powder inhaler in subjects with chronic obstructive pulmonary disease (Study Number: CTT116855, Eudra-CT Number: 2013-003075-35).   | Title: A phase III, 52 weeks, randomised, double-blind, 3-arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF/UMEC/VI with the fixed dose dual combinations of FF/VI and UMEC/VI, all administered once-daily in the morning via a dry powder inhaler in subjects with chronic obstructive pulmonary disease (Study Number: CTT116855, Eudra-CT Number: 2013-003075-35).   | Title: A phase III, 52 weeks, randomised, double-blind, 3-arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF/UMEC/VI with the fixed dose dual combinations of FF/VI and UMEC/VI, all administered once-daily in the morning via a dry powder inhaler in subjects with chronic obstructive pulmonary disease (Study Number: CTT116855, Eudra-CT Number: 2013-003075-35).   | Title: A phase III, 52 weeks, randomised, double-blind, 3-arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF/UMEC/VI with the fixed dose dual combinations of FF/VI and UMEC/VI, all administered once-daily in the morning via a dry powder inhaler in subjects with chronic obstructive pulmonary disease (Study Number: CTT116855, Eudra-CT Number: 2013-003075-35).   | Title: A phase III, 52 weeks, randomised, double-blind, 3-arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF/UMEC/VI with the fixed dose dual combinations of FF/VI and UMEC/VI, all administered once-daily in the morning via a dry powder inhaler in subjects with chronic obstructive pulmonary disease (Study Number: CTT116855, Eudra-CT Number: 2013-003075-35).   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                                                                                                                                                                         | Study Number: CTT116855, Eudra-CT Number: 2013-003075-35                                                                                                                                                                                                                                                                                                                                                                                 | Study Number: CTT116855, Eudra-CT Number: 2013-003075-35                                                                                                                                                                                                                                                                                                                                                                                 | Study Number: CTT116855, Eudra-CT Number: 2013-003075-35                                                                                                                                                                                                                                                                                                                                                                                 | Study Number: CTT116855, Eudra-CT Number: 2013-003075-35                                                                                                                                                                                                                                                                                                                                                                                 |
| Design                                                                                                                                                                                                                                                                                                                                                                                                                                   | Phase III, randomised, double blind, 3 arm parallel group, multicentre, multinational                                                                                                                                                                                                                                                                                                                                                    | Phase III, randomised, double blind, 3 arm parallel group, multicentre, multinational                                                                                                                                                                                                                                                                                                                                                    | Phase III, randomised, double blind, 3 arm parallel group, multicentre, multinational                                                                                                                                                                                                                                                                                                                                                    | Phase III, randomised, double blind, 3 arm parallel group, multicentre, multinational                                                                                                                                                                                                                                                                                                                                                    |
| Design                                                                                                                                                                                                                                                                                                                                                                                                                                   | Duration of main phase: Duration of Run-in phase: Duration of Follow-up phase:                                                                                                                                                                                                                                                                                                                                                           | Duration of main phase: Duration of Run-in phase: Duration of Follow-up phase:                                                                                                                                                                                                                                                                                                                                                           | 52 weeks 2 weeks 1 weeks                                                                                                                                                                                                                                                                                                                                                                                                                 | 52 weeks 2 weeks 1 weeks                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Hypothesis                                                                                                                                                                                                                                                                                                                                                                                                                               | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                              | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                              | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                              | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Treatments groups                                                                                                                                                                                                                                                                                                                                                                                                                        | FF/UMEC/VI                                                                                                                                                                                                                                                                                                                                                                                                                               | FF/UMEC/VI                                                                                                                                                                                                                                                                                                                                                                                                                               | FF/UMEC/VI 1 puff once in the morning (100/62.5/25 mcg per day), 52 weeks, n=4151, randomized                                                                                                                                                                                                                                                                                                                                            | FF/UMEC/VI 1 puff once in the morning (100/62.5/25 mcg per day), 52 weeks, n=4151, randomized                                                                                                                                                                                                                                                                                                                                            |
| Treatments groups                                                                                                                                                                                                                                                                                                                                                                                                                        | FF/VI                                                                                                                                                                                                                                                                                                                                                                                                                                    | FF/VI                                                                                                                                                                                                                                                                                                                                                                                                                                    | FF/VI 1 puff once in the morning (100/25 mcg per day), 52 weeks, n=4134, randomized                                                                                                                                                                                                                                                                                                                                                      | FF/VI 1 puff once in the morning (100/25 mcg per day), 52 weeks, n=4134, randomized                                                                                                                                                                                                                                                                                                                                                      |
| Treatments groups                                                                                                                                                                                                                                                                                                                                                                                                                        | UMEC/VI                                                                                                                                                                                                                                                                                                                                                                                                                                  | UMEC/VI                                                                                                                                                                                                                                                                                                                                                                                                                                  | UMEC/VI 1 puff once in the morning (62.5/25 mcg per day), 52 weeks, n=2070, randomized                                                                                                                                                                                                                                                                                                                                                   | UMEC/VI 1 puff once in the morning (62.5/25 mcg per day), 52 weeks, n=2070, randomized                                                                                                                                                                                                                                                                                                                                                   |
| Endpoints and definitions                                                                                                                                                                                                                                                                                                                                                                                                                | Primary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                         | COPD exacerbation rate                                                                                                                                                                                                                                                                                                                                                                                                                   | Annual rate of moderate/severe COPD exacerbations (on-treatment)                                                                                                                                                                                                                                                                                                                                                                         | Annual rate of moderate/severe COPD exacerbations (on-treatment)                                                                                                                                                                                                                                                                                                                                                                         |
| Endpoints and definitions                                                                                                                                                                                                                                                                                                                                                                                                                | Secondary endpoints                                                                                                                                                                                                                                                                                                                                                                                                                      | Time to first exacerbation                                                                                                                                                                                                                                                                                                                                                                                                               | Time to first on-treatment moderate/severe exacerbation                                                                                                                                                                                                                                                                                                                                                                                  | Time to first on-treatment moderate/severe exacerbation                                                                                                                                                                                                                                                                                                                                                                                  |
| Endpoints and definitions                                                                                                                                                                                                                                                                                                                                                                                                                | Secondary endpoints                                                                                                                                                                                                                                                                                                                                                                                                                      | trough FEV1                                                                                                                                                                                                                                                                                                                                                                                                                              | Change from baseline in trough FEV1 at Week 52                                                                                                                                                                                                                                                                                                                                                                                           | Change from baseline in trough FEV1 at Week 52                                                                                                                                                                                                                                                                                                                                                                                           |
| Endpoints and definitions                                                                                                                                                                                                                                                                                                                                                                                                                | Secondary endpoints                                                                                                                                                                                                                                                                                                                                                                                                                      | SGRQ                                                                                                                                                                                                                                                                                                                                                                                                                                     | Change from baseline in SGRQ Total Score at Week 52                                                                                                                                                                                                                                                                                                                                                                                      | Change from baseline in SGRQ Total Score at Week 52                                                                                                                                                                                                                                                                                                                                                                                      |
| Database lock                                                                                                                                                                                                                                                                                                                                                                                                                            | Database lock                                                                                                                                                                                                                                                                                                                                                                                                                            | Database lock                                                                                                                                                                                                                                                                                                                                                                                                                            | Database lock                                                                                                                                                                                                                                                                                                                                                                                                                            | Database lock                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                     | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                     | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                     | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                     | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Analysis description                                                                                                                                                                                                                                                                                                                                                                                                                     | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                         | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                         | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                         | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Analysis population and time point description                                                                                                                                                                                                                                                                                                                                                                                           | Intent to treat, week 52, comparison FF/UMEC/VI vs. UMEC/VI                                                                                                                                                                                                                                                                                                                                                                              | Intent to treat, week 52, comparison FF/UMEC/VI vs. UMEC/VI                                                                                                                                                                                                                                                                                                                                                                              | Intent to treat, week 52, comparison FF/UMEC/VI vs. UMEC/VI                                                                                                                                                                                                                                                                                                                                                                              | Intent to treat, week 52, comparison FF/UMEC/VI vs. UMEC/VI                                                                                                                                                                                                                                                                                                                                                                              |
|                                                                                                                                                                                                                                                                                                                                                                                                                                          | Treatment groups                                                                                                                                                                                                                                                                                                                                                                                                                         | Treatment groups                                                                                                                                                                                                                                                                                                                                                                                                                         | FF/UMEC/VI                                                                                                                                                                                                                                                                                                                                                                                                                               | UMEC/VI                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                          | Annual rate of moderate/severe COPD exacerbations (on-treatment)                                                                                                                                                                                                                                                                                                                                                                         | Annual rate of moderate/severe COPD exacerbations (on-treatment)                                                                                                                                                                                                                                                                                                                                                                         | Annual rate of moderate/severe COPD exacerbations (on-treatment)                                                                                                                                                                                                                                                                                                                                                                         | Annual rate of moderate/severe COPD exacerbations (on-treatment)                                                                                                                                                                                                                                                                                                                                                                         |
| Descriptive statistics and estimate variability                                                                                                                                                                                                                                                                                                                                                                                          | Number of subject                                                                                                                                                                                                                                                                                                                                                                                                                        | Number of subject                                                                                                                                                                                                                                                                                                                                                                                                                        | 4145                                                                                                                                                                                                                                                                                                                                                                                                                                     | 2069                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Descriptive statistics and estimate variability                                                                                                                                                                                                                                                                                                                                                                                          | Model-estimated Exacerbation Rate                                                                                                                                                                                                                                                                                                                                                                                                        | Model-estimated Exacerbation Rate                                                                                                                                                                                                                                                                                                                                                                                                        | 0.91                                                                                                                                                                                                                                                                                                                                                                                                                                     | 1.21                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| Effect estimate per comparison                  | Adjusted mean difference (95% CI)                                                                                                                                    | 0.75 (0.70; 0.81)                                                                                                                                                    | 0.75 (0.70; 0.81)                                                                                                                                                    |
|-------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                 | Time to First moderate/severe COPD exacerbations (on-treatment)                                                                                                      | Time to First moderate/severe COPD exacerbations (on-treatment)                                                                                                      | Time to First moderate/severe COPD exacerbations (on-treatment)                                                                                                      |
| Descriptive statistics and estimate variability | Number of subject                                                                                                                                                    | 1959                                                                                                                                                                 | 1036                                                                                                                                                                 |
| Descriptive statistics and estimate variability | Probably of exacerbation (%)                                                                                                                                         | 49.9 53.3                                                                                                                                                            | 49.9 53.3                                                                                                                                                            |
| Effect estimate per comparison                  | Hazard ratio (95% CI)                                                                                                                                                | 0.84 (0.78; 0.91)                                                                                                                                                    | 0.84 (0.78; 0.91)                                                                                                                                                    |
|                                                 | Change from baseline in trough FEV1 at Week 52                                                                                                                       | Change from baseline in trough FEV1 at Week 52                                                                                                                       | Change from baseline in trough FEV1 at Week 52                                                                                                                       |
|                                                 | Number of subject                                                                                                                                                    | 3366                                                                                                                                                                 | 1490                                                                                                                                                                 |
| Descriptive statistics and estimate variability | LS mean change from Baseline (SE) [L]                                                                                                                                | 0.094 (0.0042)                                                                                                                                                       | 0.040 (0.0063)                                                                                                                                                       |
| Effect estimate per comparison                  | Adjusted mean difference (95% CI) [L] p-value                                                                                                                        | 0.054 (0.039; 0.069)                                                                                                                                                 | 0.054 (0.039; 0.069)                                                                                                                                                 |
|                                                 |                                                                                                                                                                      | ˂ 0.001                                                                                                                                                              | ˂ 0.001                                                                                                                                                              |
|                                                 | Change from baseline in SGRQ Total Score at Week 52                                                                                                                  | Change from baseline in SGRQ Total Score at Week 52                                                                                                                  | Change from baseline in SGRQ Total Score at Week 52                                                                                                                  |
|                                                 | Number of subject                                                                                                                                                    | 3318                                                                                                                                                                 | 1470                                                                                                                                                                 |
| Descriptive statistics and estimate variability | LS mean change from Baseline (SE) [L]                                                                                                                                | -5.5 (0.23)                                                                                                                                                          | -3.7 (0.35)                                                                                                                                                          |
| Effect estimate per comparison                  | Adjusted mean difference (95% CI) [L]                                                                                                                                | -1.8 (-2.6; -1.0)                                                                                                                                                    | -1.8 (-2.6; -1.0)                                                                                                                                                    |
|                                                 | p-value                                                                                                                                                              | ˂ 0.001                                                                                                                                                              | ˂ 0.001                                                                                                                                                              |
| Analysis population and time point description  | Intent to treat, week 52, comparison FF/UMEC/VI vs. FF/VI                                                                                                            | Intent to treat, week 52, comparison FF/UMEC/VI vs. FF/VI                                                                                                            | Intent to treat, week 52, comparison FF/UMEC/VI vs. FF/VI                                                                                                            |
|                                                 | Treatment groups                                                                                                                                                     | FF/UMEC/VI                                                                                                                                                           | FF/VI                                                                                                                                                                |
|                                                 | Annual rate of moderate/severe COPD exacerbations (on-treatment)                                                                                                     | Annual rate of moderate/severe COPD exacerbations (on-treatment)                                                                                                     | Annual rate of moderate/severe COPD exacerbations (on-treatment)                                                                                                     |
| Descriptive statistics and estimate variability | Number of subject                                                                                                                                                    | 4145                                                                                                                                                                 | 4133                                                                                                                                                                 |
|                                                 | Model-estimated Exacerbation Rate                                                                                                                                    | 0.91                                                                                                                                                                 | 1.07                                                                                                                                                                 |
| Effect estimate per comparison                  | Adjusted mean difference (95% CI)                                                                                                                                    | 0.85 (0.80; 0.90)                                                                                                                                                    | 0.85 (0.80; 0.90)                                                                                                                                                    |
|                                                 | Time to First moderate/severe COPD exacerbations (on-treatment)                                                                                                      | Time to First moderate/severe COPD exacerbations (on-treatment)                                                                                                      | Time to First moderate/severe COPD exacerbations (on-treatment)                                                                                                      |
| Descriptive statistics and estimate variability | Number of subject                                                                                                                                                    | 1959                                                                                                                                                                 | 2039                                                                                                                                                                 |
|                                                 | Probably of exacerbation (%)                                                                                                                                         | 49.9                                                                                                                                                                 | 53.7                                                                                                                                                                 |
| Effect estimate per comparison                  | Hazard ratio (95% CI)                                                                                                                                                | 0.85 (0.80; 0.91)                                                                                                                                                    | 0.85 (0.80; 0.91)                                                                                                                                                    |
|                                                 | Change from baseline in trough FEV1 at Week 52                                                                                                                       | Change from baseline in trough FEV1 at Week 52                                                                                                                       | Change from baseline in trough FEV1 at Week 52                                                                                                                       |
|                                                 | Number of subject                                                                                                                                                    | 3366                                                                                                                                                                 | 3060                                                                                                                                                                 |
| Descriptive statistics and estimate variability | LS mean change from Baseline (SE) [L]                                                                                                                                | 0.094 (0.0042)                                                                                                                                                       | -0.003 (0.0044)                                                                                                                                                      |
| Effect estimate per comparison                  | Adjusted mean difference (95% CI) [L]                                                                                                                                | 0.097 (0.085; 0.109)                                                                                                                                                 | 0.097 (0.085; 0.109)                                                                                                                                                 |
|                                                 | p-value                                                                                                                                                              | ˂ 0.001                                                                                                                                                              | ˂ 0.001                                                                                                                                                              |
|                                                 | Change from baseline in SGRQ Total Score at Week 52                                                                                                                  | Change from baseline in SGRQ Total Score at Week 52                                                                                                                  | Change from baseline in SGRQ Total Score at Week 52                                                                                                                  |
|                                                 | Number of subject                                                                                                                                                    | 3318                                                                                                                                                                 | 3026                                                                                                                                                                 |
| Descriptive statistics and estimate variability | LS mean change from Baseline (SE) [L]                                                                                                                                | -5.5 (0.23)                                                                                                                                                          | -3.7 (0.24)                                                                                                                                                          |
| Effect estimate per comparison                  | Adjusted mean difference (95% CI) [L]                                                                                                                                | -1.8 (-2.4; -1.1)                                                                                                                                                    | -1.8 (-2.4; -1.1)                                                                                                                                                    |
|                                                 | p-value                                                                                                                                                              | ˂ 0.001                                                                                                                                                              | ˂ 0.001                                                                                                                                                              |
| Notes                                           | FF/UMEC/VI significantly reduced the model-estimated annual rate of moderate/severe COPD exacerbations by 15% and 25% compared with FF/VI and UMEC/VI, respectively. | FF/UMEC/VI significantly reduced the model-estimated annual rate of moderate/severe COPD exacerbations by 15% and 25% compared with FF/VI and UMEC/VI, respectively. | FF/UMEC/VI significantly reduced the model-estimated annual rate of moderate/severe COPD exacerbations by 15% and 25% compared with FF/VI and UMEC/VI, respectively. |

## b) Supportive Study -200812

<div style=\"page-break-after: always\"></div>

## Primary endpoint: Change from Baseline in Trough FEV1 at Week 24

In this study, the efficacy of Trelegy Ellipta has been compared to FF/VI (92/22 micrograms) + UMEC (55 micrograms),  co-administered  once  daily  as  a  multi-inhaler  therapy,  in  a  multicentre,  randomised, double-blind 24-week study in patients with COPD with a history of moderate or severe exacerbations within the prior 12 months.

The  study  met  its  primary  efficacy  endpoint  and  demonstrated  non-inferiority  of  Trelegy  Ellipta  to FF/VI+UMEC in the improvement from baseline in trough FEV1 at Week 24.  The lower bound of the CI was greater than the pre specified non-inferiority margin of -50 mL.

Table 23: Analysis of Change from Baseline in Trough FEV1 at Week 24 (modified Per Protocol Population)

|                                            | Trelegy Ellipta (n=478)       | FF/VI+UMEC (n=478)            | Trelegy Ellipta vs FF/VI+UMEC   |
|--------------------------------------------|-------------------------------|-------------------------------|---------------------------------|
| Trough FEV 1 (L) at Week 24                |                               |                               |                                 |
| LS Mean Change from Baseline (SE) (95% CI) | 0.113 (0.0112) (0.091, 0.135) | 0.095 (0.0116) (0.072, 0.117) |                                 |
| Treatment Difference (95% CI)              |                               |                               | 0.018 (-0.013, 0.050)           |

## 2.5.1. Discussion on clinical efficacy

## Design and conduct of clinical studies

Common  efficacy  endpoints  in  Studies  CTT116855  and  200812  include  time  to  first  moderate/severe COPD exacerbation,  trough  FEV1,  and  results  for  the  SGRQ  and  TDI  scores  with  responder  analyses. Additional efficacy endpoints that were included only in Study CTT116855 include the primary endpoint of moderate/severe exacerbations  of  COPD,  the  annual  rate  of  severe  exacerbations,  all-cause  mortality, rescue medication use, and night-time awakenings.

## Efficacy data and additional analyses

Key findings from Study CTT116855 are:

- FF/UMEC/VI  demonstrated  a  statistically  significant  and  clinically  meaningful  reduction  in  the annual  rate  of  on-treatment  moderate/severe  COPD  exacerbations  compared  with  FF/VI  (15% reduction, p&lt;0.001) and UMEC/VI (25% reduction, p&lt;0.001).
- In  a  sensitivity  analysis,  FF/UMEC/VI  demonstrated  a  statistically  significant  reduction  in  the annual rate of on- and off-treatment moderate/severe COPD exacerbations compared with FF/VI (11% reduction, p&lt;0.001) and UMEC/VI (20% reduction, p&lt;0.001).
- FF/UMEC/VI demonstrated a statistically significant decreased risk of an on-treatment moderate/severe COPD exacerbation compared with FF/VI (hazard ratio [HR] of 0.85, p&lt;0.001) and  UMEC/VI  (HR  of  0.84,  p&lt;0.001),  corresponding  to  risk  reductions  of  14.8%  and  16.0%, respectively (based on analysis of time to first event) with similar results including both on- and off-treatment data (risk reductions 12.8% and 14.5%, respectively, p&lt;0.001).

<div style=\"page-break-after: always\"></div>

- FF/UMEC/VI demonstrated a statistically significant reduction in the annual rate of on-treatment severe COPD exacerbations (i.e., resulting in hospitalisation or death) compared with UMEC/VI (34% reduction, p&lt;0.001). The reduction in the on-treatment annual rate of on-treatment severe COPD exacerbations for FF/UMEC/VI compared with FF/VI was not statistically significant (13% reduction, p=0.064).
- Regardless of baseline blood eosinophil count subgroup (i.e., &lt;150 cells/µL and ≥ 150 cells/µL) treatment with FF/UMEC/VI resulted in a statistically significant reduction in the annual rate of on treatment  moderate/severe  exacerbations  compared  with  FF/VI  (both  p≤0.003)  and  compared with UMEC/VI (both p≤0.034).
- FF/UMEC/VI demonstrated a statistically significant reduction in the risk of on-treatment all-cause mortality compared with UMEC/VI (HR: 0.58; 95% CI: 0.38, 0.88; p=0.011, corresponding to a risk reduction of 42.1%).  For the comparison of FF/UMEC/VI and FF/VI, the risk of on treatment all-cause mortality was similar (HR: 0.95; 95% CI: 0.64, 1.40, p=0.780, corresponding to a risk reduction of 5.5%). When both on-and off treatment mortality data were included in the analysis, the significant risk reduction in all-cause mortality was maintained for FF/UMEC/VI compared with UMEC/VI.
- FF/UMEC/VI  demonstrated  a  statistically  significant  improvement  in  trough  FEV1  at  Week  52 compared  with  FF/VI  (mean  treatment  difference  of  97mL,  p&lt;0.001)  and  UMEC/VI  (mean treatment difference of 54mL, p&lt;0.001).
- FF/UMEC/VI demonstrated a statistically significant improvement of -5.5 points from baseline in SGRQ Total Score at Week 52 compared with FF/VI (mean treatment difference of -1.8 units, p&lt;0.001) and UMEC/VI (mean treatment difference of -1.8 units, p&lt;0.001).
- FF/UMEC/VI  demonstrated  statistically  significant  greater  odds  of  being  a  responder  vs.  nonresponder based on SGRQ Total Score (response defined as a decrease in score from baseline of 4 or more) at Week 52 compared with FF/VI (odds ratio 1.41, p&lt;0.001) and UMEC/VI (odds ratio 1.41, p&lt;0.001).
- FF/UMEC/VI  demonstrated  a  statistically  significant  reduction  in  subject-recorded  daily  use  of rescue albuterol compared with FF/VI and UMEC/VI when evaluated as both the mean number of occasions  of  rescue  use  per  day  and  the  percentage  of  rescue-free  days  (p&lt;0.001  for  both comparisons).
- FF/UMEC/VI demonstrated a statistically significant reduction in the mean number of night-time awakenings per night compared with UMEC/VI (p&lt;0.001 for all four weekly analysis periods over 52 weeks) and FF/VI (p≤0.021 for all analysis periods, except for Weeks 1-4 and Weeks 33-36 which were not statistically significant different).

The supporting Study 200812 demonstrated the non-inferiority of FF/UMEC/VI to FF/VI+UMEC multiple inhaler triple therapy for the improvement in lung function based on the primary endpoint of trough FEV1 at Week 24. Additionally, the comparability of both treatments was supported by results for the SGRQ and  TDI  scores  and  the  proportion  of  subjects  who  reported  an  on  treatment  moderate/severe  COPD exacerbation.

While  the  MAH  has  indeed  demonstrated  the  superiority  of  the  triple  combination  over  the  dual components,  and  the  non-inferiority  of  the  triple  combination  over  the  components  administered

<div style=\"page-break-after: always\"></div>

separately but coincidentally, this in itself does not support the broadening of the indication for use as a first-line therapy. The use of the triple combination is currently recommended only as a step-up from dual therapy. However it is agreed that the step up from the dual therapy LABA/LAMA is considered sufficiently demonstrated and this is introduced in the section 4.1.

It is agreed that information on the effect of the product on exacerbations is clinically useful, and so this information is included in section 5.1, with a cross-reference to that section included in section 4.1.

## 2.5.2. Conclusions on the clinical efficacy

Based on the assessment of the clinical data, the SmPC is updated to reflect the changes above discussed. (Please refer also to the section update of PI later in the report).

## 2.6. Clinical safety

## Introduction

This  section  focuses  on  the  safety  data  from  the  pivotal  study  CTT116855  due  to  the  volume  of  data (10355 subjects for 1 year). Safety data from the supportive study 200812 (1055 subjects for 6 months) are briefly summarized at the end of this Section.

## Knowledge on the safety profile

There  are  known  pharmacological  effects  of  ICS,  LAMAs,  and  LABAs.    For  ICS,  these  include hypothalamic-pituitary-adrenal-axis effects, local oropharyngeal effects, and ocular effects.  In addition, in patients with COPD, treatment with ICS has been associated with bone disorders (specifically, disorders associated with decreased bone mineral density and fractures) and pneumonia. For LAMAs, these include CV  effects,  ocular  disorders,  urinary  retention,  gastrointestinal  disorders,  along  with  anticholinergic effects  (e.g.,  dry  mouth,  cough)  and  for  LABAs,  these  include  CV  and  neuromuscular  effects.  The potential for treatment with FF/UMEC/VI to result in these effects was evaluated in the clinical trials.

## Patient exposure

Subject exposure data were summarised for the ITT Population.

## a) CTT116855

A total of 10,355 subjects were randomised and included in the CTT116855 ITT Population; 4151 subjects to the FF/UMEC/VI group, 4134 subjects to the FF/VI group, and 2070 subjects to the UMEC/VI group.

Mean duration of treatment exposure was higher in the FF/UMEC/VI group (325.9 days) compared with the FF/VI (304.5 days) and UMEC/VI (298.7 days) groups.  A total of 76%, 69%, and 68% of subjects in the  FF/UMEC/VI,  FF/VI,  and  UMEC/VI  groups,  respectively,  were  exposed  to  treatment  for  51  to  53 weeks.  The proportion of subjects exposed to treatment in each duration category was higher in the FF/UMEC/VI group than in the FF/VI or the UMEC/VI group throughout the 52 weeks of the study.  The reduction in the exposure rate during the last week of the study, Week 52, ranging from 53% to 59 % across groups, was a result of the study visit window.

## b) 200812

<div style=\"page-break-after: always\"></div>

Mean duration of treatment exposure was the same in both treatment groups (162.1 days in FF/UMEC/VI and 162.1 days in FF/VI+UMEC).  Greater than 90% of subjects in both treatments groups were exposed to  treatment  for  23  to  25  weeks,  and  94%  and  95%  of  subjects  were  exposed  to  treatment  for  ≥20 weeks in the FF/UMEC/VI and FF/VI+UMEC groups, respectively.  The proportion of subjects exposed to treatment in each duration category was similar between the treatment groups throughout the study.

## Adverse Events

## a) CTT116855

The most frequently reported on-treatment AEs were viral URTI and COPD.  The incidence and exposureadjusted rate of viral URTI were similar across treatment groups. The incidence of COPD was 11% in the FF/UMEC/VI and FF/VI groups and 13% in the UMEC/VI group, with a lower exposure adjusted rate in the FF/UMEC/VI group (152.9) compared with the FF/VI (172.1) and UMEC/VI (207.3) groups.  Pneumonia and oral candidiasis had higher incidences and exposure-adjusted rates in the ICS-containing groups (i.e., FF/UMEC/VI and FF/VI) compared with the UMEC/VI group.

Table 24: The 10 Most Frequent On-treatment Adverse Events in Each Treatment Group (Study CTT116855, ITT Population)

| Adverse Event (Preferred Term)         | FF/UMEC/VI N=4151   | FF/UMEC/VI N=4151   | FF/VI N=4134   | FF/VI N=4134   | UMEC/VI N=2070   | UMEC/VI N=2070   |
|----------------------------------------|---------------------|---------------------|----------------|----------------|------------------|------------------|
|                                        | n (%)               | Rate [#] 1          | n (%)          | Rate [#] 1     | n (%)            | Rate [#] 1       |
| Total duration at risk (subject-years) | 3714.9              | 3714.9              | 3457.9         | 3457.9         | 1698.3           | 1698.3           |
| Viral URTI                             | 521 (13)            | 191.9 [713]         | 479 (12)       | 190.3 [658]    | 223 (11)         | 186.7 [317]      |
| COPD                                   | 455 (11)            | 152.9 [568]         | 472 (11)       | 172.1 [595]    | 279 (13)         | 207.3 [352]      |
| URTI                                   | 299 (7)             | 108.5 [403]         | 283 (7)        | 111.0 [384]    | 117 (6)          | 95.4 [162]       |
| Pneumonia                              | 298 (7)             | 88.6 [329]          | 264 (6)        | 86.8 [300]     | 93 (4)           | 57.7 [98]        |
| Headache                               | 233 (6)             | 103.6 [385]         | 198 (5)        | 96.3 [333]     | 103 (5)          | 83.0 [141]       |
| Back pain                              | 148 (4)             | 49.0 [182]          | 140 (3)        | 48.0 [166]     | 83 (4)           | 59.5 [101]       |
| Bronchitis                             | 152 (4)             | 47.1 [175]          | 130 (3)        | 47.1 [163]     | 73 (4)           | 50.6 [86]        |
| Oral candidiasis                       | 161 (4)             | 54.6 [203]          | 146 (4)        | 50.9 [176]     | 41 (2)           | 29.4 [50]        |
| Cough                                  | 145 (3)             | 45.2 [168]          | 117 (3)        | 37.0 [128]     | 58 (3)           | 44.2 [75]        |
| Arthralgia                             | 122 (3)             | 36.6 [136]          | 86 (2)         | 27.8 [96]      | 46 (2)           | 34.2 [58]        |
| Sinusitis                              | 104 (3)             | 32.0 [119]          | 98 (2)         | 33.3 [115]     | 45 (2)           | 27.7 [47]        |
| Dyspnoea                               | 82 (2)              | 26.6 [99]           | 95 (2)         | 31.8 [110]     | 52 (3)           | 37.1 [63]        |
| Pharyngitis                            | 82 (2)              | 29.1 [108]          | 81 (2)         | 25.7 [89]      | 48 (2)           | 34.7 [59]        |

## b) 200812

The most frequently reported AEs in the FF/UMEC/VI and FF/VI+UMEC groups were viral URTI (11% and 10%, respectively), headache (6% in both), and COPD (4% and 6%, respectively).  The remaining most frequent AEs were reported for ≤5% of subjects in either treatment group and with a similar incidence in both treatment groups.

<div style=\"page-break-after: always\"></div>

Table 25: The 10 Most Frequent 1  On-Treatment AEs in Each Treatment Group (ITT Population, Study 200812)

| Preferred Term   | FF/UMEC/VI (N=527)   | FF/UMEC/VI (N=527)   | FF/VI+UMEC (N=528)   | FF/VI+UMEC (N=528)   |
|------------------|----------------------|----------------------|----------------------|----------------------|
|                  | n (%)                | Rate2 [#Events]      | n (%)                | Rate2 [# Events]     |
| Viral URTI       | 56 (11)              | 295.1 [69]           | 52 (10)              | 260.3 [61]           |
| Headache         | 32 (6)               | 239.5 [56]           | 33 (6)               | 230.4 [54]           |
| COPD             | 23 (4)               | 119.7 [28]           | 31 (6)               | 153.6 [36]           |
| URTI             | 18 (3)               | 81.2 [19]            | 24 (5)               | 123.8 [29]           |
| Influenza        | 17 (3)               | 77.0 [18]            | 18 (3)               | 76.8 [18]            |
| Pneumonia        | 14 (3)               | 72.0 [17]            | 18 (3)               | 76.8 [18]            |
| Pharyngitis      | 12 (2)               | 51.3 [12]            | 16 (3)               | 76.8 [18]            |
| Back Pain        | 13 (2)               | 55.6 [13]            | 8 (2)                | 42.7 [10]            |
| Bronchitis       | 9 (2)                | 42.8 [10]            | 7 (1)                | 34.1 [8]             |
| Hypertension     | 8 (2)                | 38.5 [9]             | 11 (2)               | 55.5 [13]            |
| Cough            | 5 (<1)               | 25.7 [6]             | 8 (2)                | 42.7 [10]            |

## Serious adverse event/deaths/other significant events On-Treatment Fatal Adverse Events

## a) CTT116855

On-treatment fatal SAEs were reported for 68 (2%), 76 (2%), and 49 (2%) subjects in the FF/UMEC/VI, FF/VI,  and  UMEC/VI  groups,  respectively,  with  respective  exposure-adjusted  rates  of  26.4,  27.8,  and 38.3.    COPD  was  the  most  frequently  reported  fatal  SAE  in  each  treatment  group,  reported  with  an incidence of &lt;1% in each treatment group.

The events in the SOC of Cardiac disorders were reported with an incidence of &lt;1% in each treatment group.

Pneumonia was also reported with an incidence of &lt;1% in each treatment group.

## b) 200812

A total of 10 on treatment fatal SAEs were reported for 8 subjects (4 subjects [&lt;1%] in each treatment group). The most commonly reported on treatment fatal SAEs (PTs) were of 'pneumonia' (reported for 1 subject  in  the  FF/UMEC/VI  group  and  2  subjects  in  the  FF/VI+UMEC  group),  'COPD'  (reported  for  1 subject in each treatment group), and 'acute MI' (reported for 1 subject in each treatment group).

## Non-Fatal Serious Adverse Events

## a) CTT116855

The incidence of on-treatment non-fatal SAEs was similar across treatment groups (19% to 21% across groups) with exposure-adjusted rates of 405.4, 395.9, and 405.1 in the FF/UMEC/VI, FF/VI, and UMEC/VI groups, respectively.  The most common non-fatal on treatment SAEs were COPD (10% to 13% across groups) and pneumonia (2% to 4% across groups).  The exposure-adjusted rate of COPD was lower for the  FF/UMEC/VI  (145.6)  and  FF/VI  (158.2)  groups  compared  with  the  UMEC/VI  group  (192.0).    The exposure-adjusted rate of pneumonia was higher for ICS-containing groups (i.e., FF/UMEC/VI [50.6] and FF/VI [46.3]) compared with the UMEC/VI group (30.6).

<div style=\"page-break-after: always\"></div>

Table 26: On-treatment Non-fatal SAEs Occurring in ≥ 1% Subjects in Any Treatment Group (Study CTT116855, ITT Population)

| Non-fatal SAE System Organ Class                                     | FF/UMEC/VI N=4151   | FF/UMEC/VI N=4151       | FF/VI N=4134      | FF/VI N=4134            | UMEC/VI N=2070    | UMEC/VI N=2070          |
|----------------------------------------------------------------------|---------------------|-------------------------|-------------------|-------------------------|-------------------|-------------------------|
| Preferred Term                                                       | n (%)               | Rate [#] 1              | n (%)             | Rate [#] 1              | n (%)             | Rate [#] 1              |
| Total duration at risk (subject-years)                               | 3714.9              | 3714.9                  | 3457.9            | 3457.9                  | 1698.3            | 1698.3                  |
| Any Non-fatal SAE                                                    | 847 (20)            | 405.4 [1506]            | 801 (19)          | 395.9 [1369]            | 433 (21)          | 405.1 [688]             |
| Respiratory, thoracic, and mediastinal disorders COPD                | 465 (11) 431 (10)   | 172.6 [641] 145.6 [541] | 469 (11) 435 (11) | 182.5 [631] 158.2 [547] | 277 (13) 261 (13) | 214.9 [365] 192.0 [326] |
| Infections and infestations Pneumonia                                | 253 (6) 175 (4)     | 84.3 [313] 50.6 [188]   | 245 (6) 147 (4)   | 85.3 [295] 46.3 [160]   | 91 (4) 51 (2)     | 62.4 [106] 30.6 [52]    |
| Cardiac disorders                                                    | 99 (2)              | 36.3 [135]              | 81 (2)            | 25.2 [87]               | 49 (2)            | 34.7 [59]               |
| Neoplasms benign, malignant, and unspecified (incl cysts and polyps) | 57 (1)              | 16.7 [62]               | 50 (1)            | 15.3 [53]               | 21 (1)            | 13.0 [22]               |
| Gastrointestinal disorders                                           | 51 (1)              | 15.9 [59]               | 52 (1)            | 16.8 [58]               | 17 (<1)           | 10.0 [17]               |
| Injury, poisoning, and procedural complications                      | 49 (1)              | 15.9 [59]               | 40 (<1)           | 13.9 [48]               | 14 (<1)           | 9.4 [16]                |
| Nervous system disorders                                             | 47 (1)              | 14.3 [53]               | 28 (<1)           | 8.4 [29]                | 13 (<1)           | 7.7 [13]                |

## b) 200812

The incidence of on treatment non-fatal SAEs was similar between the treatment groups. There were 69 on treatment non-fatal SAEs reported for 50 subjects (9%) in the FF/UMEC/VI group and 86 on treatment non-fatal  SAEs  for  54  subjects  (10%)  in  the  FF/VI+UMEC  group.    'COPD'  was  the  most  frequently reported SAE in both treatment groups.

## Other Significant Adverse Events

Adverse Events Leading to Permanent Discontinuation of Investigational Product or Withdrawal.

## a) CTT116855

The incidence of on-treatment AEs that led to permanent discontinuation or withdrawal was 6% to 9% across treatment groups with lower exposure-adjusted rates in the FF/UMEC/VI (92.1) group compared with the FF/VI (128.7) and UMEC/VI (144.3) groups.

Table 27: On-treatment Adverse Events Leading to Permanent Discontinuation of Study Treatment or Withdrawal from the Study in ≥ 1% of Subjects in Any Treatment Group (Study CTT116855, ITT Population)

| Adverse Events Leading to Discontinuation of Study Treatment or Withdrawal from the Study System Organ Class   | FF/UMEC/VI 100/62.5/25 N=4151   | FF/UMEC/VI 100/62.5/25 N=4151   | FF/VI 100/25 N=4134   | FF/VI 100/25 N=4134   | UMEC/VI 62.5/25 N=2070   | UMEC/VI 62.5/25 N=2070   |
|----------------------------------------------------------------------------------------------------------------|---------------------------------|---------------------------------|-----------------------|-----------------------|--------------------------|--------------------------|
| Preferred Term                                                                                                 | n (%)                           | Rate [#] 1                      | n (%)                 | Rate [#] 1            | n (%)                    | Rate [#] 1               |
| Any Adverse event leading to discontinuation of treatment or withdrawal from study                             | 252 (6)                         | 92.1 [342]                      | 327 (8)               | 128.7 [445]           | 187 (9)                  | 144.3 [245]              |
| Respiratory, thoracic, and mediastinal disorders                                                               | 109 (3)                         | 32.0 [119]                      | 109 (3)               | 32.0 [119]            | 104 (5)                  | 68.9 [117]               |
| COPD                                                                                                           | 65 (2)                          | 17.5 [65]                       | 93 (2)                | 26.9 [93]             | 72 (3)                   | 42.4 [72]                |

## b) 200812

<div style=\"page-break-after: always\"></div>

The  incidence  of  on  treatment  AEs  that  led  to  withdrawal  from  the  study  were  similar  between  the treatment  groups.    Three  percent  of  subjects  in  the  FF/UMEC/VI  group  and  2%  of  subject  in  the FF/VI+UMEC group experienced of on treatment AEs that led to withdrawal from the study, the most common of which was 'COPD'.

## Adverse Events of Special Interest

Adverse events of special interest for Studies CTT116855 and 200812 have been defined as AEs which have  specified  areas  of  interest  for  FF,  UMEC,  or  VI  or  for  the  COPD  population,  given  their  known mechanisms of action.

For study CTT116855, the incidence and exposure-adjusted rates in other AESI groups were generally similar  across  treatment  groups,  including  those  associated  with  ICS-containing  groups  (e.g.,  Ocular effects and Decreased bone mineral density and associated fractures).

Of  the  AESI  groups,  CV  effects  was  most  frequently  reported,  with  similar  incidences  and  exposureadjusted rates of any event in that group reported across treatment groups (10% to 11% and 157.0 to 167.2,  respectively).    Local  steroid  effects  and  Pneumonia  were  the  next  most  frequently  reported groups, and were reported at a similar incidence in the ICS-containing FF/UMEC/VI (337 subjects [8%] and 317 subjects [8%], respectively) and FF/VI (301 subjects [7%] and 292 subjects [7%], respectively) groups  and  more  frequently  compared  with  the  UMEC/VI  group  (108  subjects  [5%]  and  97  subjects [5%], respectively).

The exposure adjusted rates of any event in the Local steroid effects and Pneumonia AESI groups were higher in the FF/UMEC/VI (114.4 and 95.8, respectively) and FF/VI (107.3 and 96.6, respectively) groups compared with the UMEC/VI group (80.1 and 61.2, respectively).

## a) 200812

The  incidence  of  AESIs  was  low  in  both  treatment  groups,  with  CV  effects  being  the  most  frequently reported  (6%  in  FF/UMEC/VI  and  5%  in  FF/VI+UMEC).    The  next  most  common  AESIs  were  lower respiratory tract infections (LRTIs) excluding pneumonia (3% in FF/UMEC/VI and 2% in FF/VI+UMEC) and pneumonia (3% in FF/UMEC/VI and 4% in FF/VI+UMEC).

## Pneumonia

## a) CTT116855

There  was  a  higher  incidence  of  any  event  in  the  Pneumonia  AESI  group  in  the  ICS-containing FF/UMEC/VI  (317  subjects  [8%])  and  FF/VI  (292  subjects  [7%])  groups  compared  with  the  UMEC/VI group (97 subjects [5%])).  The proportion of pneumonia events resulting in hospitalisation was generally similar across treatment groups (207 of 346 events [60%] in the FF/UMEC/VI group, 177 of 319 events [55%]  in  the  FF/VI  group,  and  58  of  101  events  [57%]  in  the  UMEC/VI  group).    The  proportion  of pneumonia  events  associated  with  infiltrates  on  X-ray/CT  scan  was  48%  (166  of  346  events)  in  the FF/UMEC/VI group, 49% (156 of 319 events) in the FF/VI group, and 40% (40 of 101 events) in the UMEC/VI group.

Based on analysis of time to first event, the risk of any on-treatment event in the Pneumonia AESI group was similar for FF/UMEC/VI compared with FF/VI (HR: 1.02, 95% CI: 0.87, 1.19; p=0.848). The risk of

<div style=\"page-break-after: always\"></div>

any  on-treatment  event  in  the  Pneumonia  AESI  group  was  statistically  significantly  increased  for FF/UMEC/VI compared with UMEC/VI (HR: 1.53, 95% CI: 1.22, 1.92; p&lt;0.001).

Table 28: Summary of On-treatment Pneumonia Incidence (Study CTT116855, ITT Population)

| Pneumonia Details                      | FF/UMEC/VI 100/62.5/25 N=4151   | FF/UMEC/VI 100/62.5/25 N=4151   | FF/VI 100/25 N=4134   | FF/VI 100/25 N=4134   | UMEC/VI 62.5/25 N=2070   | UMEC/VI 62.5/25 N=2070   |
|----------------------------------------|---------------------------------|---------------------------------|-----------------------|-----------------------|--------------------------|--------------------------|
|                                        | n (%)                           | Rate [#] 1                      | n (%)                 | Rate[#] 1             | n (%)                    | Rate [#] 1               |
| Total duration at risk (subject-years) | 3714.9                          | 3714.9                          | 3457.9                | 3457.9                | 1698.3                   | 1698.3                   |
| Subjects with pneumonia                | 312 (8%)                        | 93.1 [346]                      | 282 (7%)              | 92.3 [319]            | 95 (5%)                  | 59.5 [101]               |
| Supported by X-ray/CT scan             | 154 (4%)                        | 44.7 [166]                      | 147 (4%)              | 45.1 [156]            | 40 (2%)                  | 23.6 [40]                |
| Pneumonias/subject, n (%)              |                                 |                                 |                       |                       |                          |                          |
| 0                                      | 3839 (92%)                      | 3839 (92%)                      | 3852 (93%)            | 3852 (93%)            | 1975 (95%)               | 1975 (95%)               |
| 1                                      | 284 (7%)                        | 284 (7%)                        | 250 (6%)              | 250 (6%)              | 89 (4%)                  | 89 (4%)                  |
| 2                                      | 24 (<1%)                        | 24 (<1%)                        | 28 (<1%)              | 28 (<1%)              | 6 (<1%)                  | 6 (<1%)                  |
| ≤ 3                                    | 4 (<1%)                         | 4 (<1%)                         | 4 (<1%)               | 4 (<1%)               | 0                        | 0                        |

1. Event rate per 1000 subject-years calculated as the number of events x 1000, divided by the total
2. duration at risk. Note: A chest X-ray/CT scan was associated with pneumonia if it was performed within the duration of the pneumonia or between -7 to +10 days (inclusive) of the date of onset. Note: Pneumonia was supported by a chest X-ray/CT scan if there was an associated X-ray/CT scan that showed the presence of infiltrates.

Figure 10: Kaplan-Meier Plot of Time to First On-treatment Event in the Pneumonia AESI Group (Study CTT116855, ITT Population) b) 200812

<!-- image -->

There  was  a  similar  incidence  of  Pneumonia  AESIs  in  the  subjects  in  the  FF/UMEC/VI  (3%)  and FF/VI+UMEC  treatment  groups  (4%).    The  incidence  of  on  treatment  serious  Pneumonia  AESIs  was

<div style=\"page-break-after: always\"></div>

similar  between  the  treatment  groups,  with  2%  in  the  FF/UMEC/VI  (all  pneumonia)  and  3%  in  the FF/VI+UMEC group.

## Cardiovascular Events

## a) CTT116855

CV effects  was  the  most frequently  reported  AESI  group  and  any  event in  that  group occurred  with a similar incidence across treatment groups (10% to 11% across groups). Overall, the exposure adjusted rates of these CV AESIs were similar across treatment groups.

The  incidence  of  ischaemic  heart  disease  (SMQ)  was  similar  across  treatment  groups  (1%  to  2%). However, the exposure-adjusted rates for FF/UMEC/VI and UMEC/VI (26.1 and 30.6, respectively) were higher compared to FF/VI (18.5).

## MACE analyses

Two analyses of MACE were performed, using broad and narrow MACE definitions.  The broad-definition MACE  included  the  ischaemic  heart  disease  SMQ  (MI  SMQ  and  other  ischaemic  heart  disease  SMQ) excluding  fatalities,  the  central  nervous  system  haemorrhages  and  cerebrovascular  conditions  SMQ excluding fatalities, and adjudicated CV deaths.  To investigate events relating specifically to MI rather than other cardiac ischaemic events, the narrow MACE definition included only the PTs of non-fatal MI and non-fatal  acute  myocardial  in  addition  to  central  nervous  system  haemorrhages  and  cerebrovascular conditions SMQ excluding fatalities.

The  incidence  and  exposure-adjusted  rates  for  any  on-treatment  MACE  events  using  the  broad  and narrow definitions were similar across treatment groups.  A total of 80 subjects (2%) in the FF/UMEC/VI group, 60 subjects (1%) in the FF/VI group, and 37 subjects (2%) in the UMEC/VI group reported any MACE (narrow definition) with exposure-adjusted rates of 22.3, 18.8, and 22.4 for FF/UMEC/VI, FF/VI, and UMEC/VI, respectively.  There were 20 (&lt;1%) adjudicated CV deaths in the FF/UMEC/VI group, 27 (&lt;1%)  in  the  FF/VI  group,  and  16  (&lt;1%)  in  the  UMEC/VI  group.    The  exposure-adjusted  rate  of adjudicated  CV  death  was  lower  in  the  FF/UMEC/VI  (5.4)  group  compared  with  the  FF/VI  (7.8)  and UMEC/VI (9.4) groups.  The exposure-adjusted rate of non-fatal central nervous system haemorrhages and cerebrovascular conditions was higher in the FF/UMEC/VI (10.8) group compared with the FF/VI (7.2) and UMEC/VI (5.9) groups.  A total of 133 subjects (3%) in the FF/UMEC/VI group, 100 subjects (2%) in the FF/VI group, and 66 subjects (3%) in the UMEC/VI group reported any MACE (broad definition) with exposure-adjusted rates of 44.7, 35.3, and 44.8 for FF/UMEC/VI, FF/VI, and UMEC/VI, respectively.

<div style=\"page-break-after: always\"></div>

Table 29: Major Adverse Cardiac Events (Study CTT116855, ITT Population)

| MACE                                                        | FF/UMEC/VI 100/62.5/25 N=4151   | FF/UMEC/VI 100/62.5/25 N=4151   | FF/VI 100/25 N=4134   | FF/VI 100/25 N=4134   | UMEC/VI 62.5/25 N=2070   | UMEC/VI 62.5/25 N=2070   |
|-------------------------------------------------------------|---------------------------------|---------------------------------|-----------------------|-----------------------|--------------------------|--------------------------|
|                                                             | n (%)                           | Rate[#] 1                       | n (%)                 | Rate [#] 1            | n (%)                    | Rate[#]1                 |
| Narrow Definition                                           |                                 |                                 |                       |                       |                          |                          |
| Any MACE                                                    | 80 (2)                          | 22.3 [83]                       | 60 (1)                | 18.8 [65]             | 37 (2)                   | 22.4 [38]                |
| Adjudicated CV death                                        | 20 (<1)                         | 5.4 [20]                        | 27 (<1)               | 7.8 [27]              | 16 (<1)                  | 9.4 [16]                 |
| Non-fatal CNShaemorrhages &cerebrovascular conditions (SMQ) | 38 (<1)                         | 10.8 [40]                       | 21 (<1)               | 7.2 [25]              | 10 (<1)                  | 5.9 [10]                 |
| Non-fatal MI (PT)                                           | 9 (<1)                          | 2.4 [9]                         | 6 (<1)                | 1.7 [6]               | 5 (≤1)                   | 2.9 [5]                  |
| Non-fatal acute MI (PT)                                     | 13 (≤1)                         | 3.8 [14]                        | 7 (<1)                | 2.0 [7]               | 7 (≤1)                   | 4.1 [7]                  |
| Broad Definition                                            |                                 |                                 |                       |                       |                          |                          |
| Any MACE                                                    | 133 (3)                         | 44.7 [166]                      | 100 (2)               | 35.3 [122]            | 66 (3)                   | 44.8 [76]                |
| Adjudicated CV death                                        | 20 (<1)                         | 5.4 [20]                        | 27 (<1)               | 7.8 [27]              | 16 (<1)                  | 9.4 [16]                 |
| Non-fatal CNS haemorrhages &cerebrovascular conditions      | 38 (≤1)                         | 10.8 [40]                       | 21 (<1)               | 7.2 [25]              | 10 (<1)                  | 5.9 [10]                 |
| Non-fatal MI (SMQ)                                          | 49 (1)                          | 14.0 [52]                       | 29 (<1)               | 9.3 [32]              | 24 (1)                   | 14.7 [25]                |
| Non-fatal other ischaemic heart disease (SMQ)               | 41 (≤1)                         | 14.5 [54]                       | 32 (<1)               | 11.0 [38]             | 25 (1)                   | 14.7 [25]                |

SourceS:CSR CTT116855RAP Table 3.046and CSR CTT116855 RAP Table3.047

1. Rate was event rate per 1000 subject-years, calculated as the number of events x 1000, divided by the total treatment exposure.

CV=cardiovascular; CNS=central nervous system; MACE=Major Adverse Cardiac Event; Ml=myocardial infarction; PT=Preferred Term; SMQ=Standardised MedDRA Query; RAP=Reporting and Analysis Plan

## ECG Findings

For the ITT Population, 12-lead ECGs were obtained at baseline (Screening) and 15 to 45 minutes postdose after 4, 28, and 52 weeks of treatment. In addition, a subset of subjects performed a pre-dose ECG in addition to the post-dose ECG at the Week 4 Visit (Pre-dose ECG Population).

ITT  Population:  At  baseline,  the  proportion  of  subjects  with  abnormal  ECG  findings  was  similar  across treatment  groups  (31%  to  32%  across  groups).  At  any  visit  post-baseline,  abnormal  findings  were reported for 1783 subjects (44%) in the FF/UMEC/VI group, 1757 subjects (44%) in the FF/VI group, and 860 subjects (44%) in the UMEC/VI group. For subjects with normal ECG findings at baseline, a worst case post-baseline shift to abnormal was reported for 584 subjects (14%) in the FF/UMEC/VI group, 602 subjects (15%) in the FF/VI group, and 297 subjects (15%) in the UMEC/VI group.

<div style=\"page-break-after: always\"></div>

Table 30: ECG Abnormalities Occurring in ≥ 3% of Subjects in Any Treatment Group (Study CTT116855, ITT Population)

| ECG Abnormality                               | FF/UMEC/VI 100/62.5/25 N=4151   | FF/UMEC/VI 100/62.5/25 N=4151   | FF/VI 100/25 N=4134    | FF/VI 100/25 N=4134    | UMECIVI 62.5/25 N=2070   | UMECIVI 62.5/25 N=2070   |
|-----------------------------------------------|---------------------------------|---------------------------------|------------------------|------------------------|--------------------------|--------------------------|
|                                               | n (%)                           | Rate [#] 1                      | n (%)                  | Rate [#] 1             | n (%)                    | Rate [#] 1               |
| Baseline 2                                    |                                 |                                 |                        |                        |                          |                          |
| n                                             | 4148                            |                                 | 4133 1555 (38)         |                        | 2068 789 (38)            |                          |
| Any abnormal ECG finding                      | 1583 (38)                       |                                 |                        |                        |                          |                          |
| Left anterior fascicular block                | 321 (8)                         |                                 | 210 (5)                |                        | 96 (5)                   |                          |
| First degree AV block (PR interval > 200msec) | 261 (6)                         |                                 | 290 (7)                |                        | 166 (8)                  |                          |
| Right bundle branch block                     | 242 (6)                         |                                 | 151 (4)                |                        | 53 (3)                   |                          |
| Ectopic supraventricular rhythm               | 223 (5)                         |                                 | 147 (4)                |                        | 79 (4)                   |                          |
| T waves flat                                  | 177 (4)                         |                                 | 194 (5)                |                        | 121 (6)                  |                          |
| T wave inversion                              | 151 (4)                         |                                 | 197 (5)                |                        | 107 (5)                  |                          |
| Ectopic ventricular rhythm                    | 141 (3)                         |                                 | 278 (7)                |                        | 134 (6)                  |                          |
| St depression                                 | 131 (3)                         |                                 | 163 (4)                |                        | 75 (4)                   |                          |
| Any time post-baseline                        | Any time post-baseline          | Any time post-baseline          | Any time post-baseline | Any time post-baseline | Any time post-baseline   | Any time post-baseline   |
| n Any abnormal ECG finding                    | 4066 2201 (54)                  | 2030.8 [7544]                   | 3962 2139 (54)         | 2057.0 [7113]          | 1974 1059 (54)           | 2003.8 [3403]            |
| Ectopic supraventricular rhythm               | 452 (11)                        | 178.5 [663]                     | 441 (11)               | 181.9 [629]            | 238 (12)                 | 197.8 [336]              |
| T waves flat                                  | 421 (10)                        | 187.9 [698]                     | 431 (11)               | 196.4 [679]            | 210 (11)                 | 190.2 [323]              |
| First degree AV block (PR interval > 200msec) | 405 (10)                        | 213.7 [794]                     | 415 (10)               | 235.4 [814]            | 180 (9)                  | 210.8 [358]              |
| Left anterior fascicular block                | 389 (10)                        | 267.6 [994]                     | 368 (9)                | 261.4 [904]            | 186 (9)                  | 276.8 [470]              |
| Ectopic ventricular rhythm                    | 370 (9)                         | 138.6 [515]                     | 329 (8)                | 126.1 [436]            | 158 (8)                  | 124.8 [212]              |
| T wave inversion                              | 297 (7)                         | 150.5 [559]                     | 312 (8)                | 166.9 [577]            | 140 (7)                  | 148.4 [252]              |
| Right bundle branch block                     | 284 (7)                         | 213.7 [794]                     | 246 (6)                | 183.9 [636]            | 113 (6)                  | 176.1 [299]              |
| St depression                                 | 262 (6)                         | 129.2 [480]                     | 294 (7)                | 150.7 [521]            | 129 (7)                  | 127.8 [217]              |
| Sinus tachycardia (rate >100 beats/min)       | 205 (5)                         | 73.2 [272]                      | 215 (5)                | 84.7 [293]             | 110 (6)                  | 81.3 [138]               |
| Other conduction                              | 132 (3)                         | 59.2 [220]                      | 166 (4)                | 83.9 [290]             | 81(4)                    | 79.5 [135]               |
| Atrial fibrillation                           | 126 (3)                         | 83.2 [309]                      | 113 (3)                | 78.1 [270]             | 51 (3)                   | 71.8 [122]               |

Sources: CSR CTT116855 RAP Table 3.081 and CSR CTT116855 RAP Table 3.083

1. Rate is event rate per 1000 subject-years, calculated as the number of reports of abnormal finding x 1000, divided by the total duration at risk.

2. Baseline abnormalities are abnormalities from the most recent ECG performed prior to first dose of study treatment.

ECG=electrocardiogram; RAP=Reporting and Analysis Plan

Pre-dose ECG Population: At baseline, abnormal ECG findings were reported for 138 subjects (38%) in the FF/UMEC/VI group, 118 subjects (36%) in the FF/VI group, and 66 subjects (42%) in the UMEC/VI group.  At  any  visit  post-baseline,  abnormal  findings  were  reported  for  190  subjects  (52%)  in  the FF/UMEC/VI group, 155 subjects (47%) in the FF/VI group, and 73 subjects (46%) in the UMEC/VI group. For  subjects  with  normal  ECG  findings  at  baseline,  a  worst  case  post-baseline  shift  to  abnormal  was reported for 57 subjects (16%) in the FF/UMEC/VI group, 44 subjects (13%) in the FF/VI group, and 12 subjects (8%) in the UMEC/VI group.

a) 200812

<div style=\"page-break-after: always\"></div>

CV AESIs were the most frequently reported AESI  group and occurred with a similar  incidence  in  the FF/UMEC/VI and FF/VI+UMEC groups (6% and 5%, respectively).  All of the CV AESI subgroups occurred at a similar incidence in both treatment groups.

## Safety in special populations

## Safety in Subgroups

Study CTT116855 specified safety subgroup summaries and analyses by gender, age, race, geographical region  (including  a  US/Non-US  sites  subgroup  for  summaries  only),  exacerbation  history,  and  CV  risk. Additional  subgroups  were  evaluated  for  pneumonia  evaluation  and  fatalities,  and  included  smoking status, BMI, and pneumonia history. Subgroup analyses were not specified for Study 200812.

The safety subgroup analyses for Study CTT116855 are summarized as follows:

- Overall,  no  notable,  clinically  relevant,  or  unexpected  differences  between  subgroups  were observed.  Where differences were observed, these were mainly due to a relatively low number of subjects and/or a low number of events.
- Female  subjects  reported  a  higher  rate  of  any  on-treatment  AE  and  male  subjects  reported  a higher  rate  of  any  on-treatment  SAEs  and  fatal  SAEs  (including  adjudicated  serious  adverse reports) for all treatment groups and AEs leading to premature discontinuation of study treatment or withdrawal from the study for FF/UMEC/VI and sFF/VI.
- Subjects in the ≤64 years of age subgroup had lower rates of AEs, SAEs and fatal SAEs (including adjudicated  serious  adverse  reports)  and  AEs  leading  to  permanent  discontinuation  of  study treatment or withdrawal from the study, while subjects within the 65 to 74 years of age subgroup had similar to higher rates of events, and subjects within the 75 to 84 years of age subgroup had higher rates of events, with the exception of the 75 to 84 years of age subgroup in the UMEC/VI group,  which  had  a  similar  or  lower  rate  of  events  compared  with  the  ITT  Population.    The UMEC/VI  group  had  the  smallest  number  of  subjects  in  the  75  to  84  years  of  age  subgroup compared with the other age subgroups; therefore, any differences found in the UMEC/VI group may  be  due  to  smaller  total  duration  at  risk.  Interpretation  of  findings  the  ≥85  years  of  age subgroup were limited due to the relatively low number of subjects (&lt;1% of the population in each treatment group).
- The rate of any on-treatment AEs, fatal SAEs and SAEs (including adjudicated serious adverse reports and adjudicated non-fatal serious adverse reports) was higher in Asian subjects compared with the overall ITT Population, with the exception of any on-treatment AEs and fatal SAEs within the FF/UMEC/VI group. Within each treatment group, the rate of adjudicated fatal serious adverse reports and AEs leading to permanent discontinuation of study treatment or withdrawal from the study was similar or lower in Asian subjects compared with the overall ITT Population.
- From  the  five  geographical  subgroups  (Western  Europe,  Asia,  North  America,  and  South America),  subjects  in  South  America  had  the  lowest  rate  of  AEs,  SAEs  (including  adjudicated serious adverse reports) and AEs leading to treatment/study discontinuation compared with the ITT Population.  The highest rates of AEs, SAEs (including adjudicated serious adverse reports) and  AEs  leading  to  treatment/study  discontinuation  compared  with  the  ITT  Population  were  in

<div style=\"page-break-after: always\"></div>

subjects in North America (FF/UMEC/VI and UMEC/VI groups) or in Asia (FF/VI).  Overall, within each  treatment  group,  subjects  in  Western  Europe  had  a  lower  rate  of  any  on-treatment  fatal SAEs.

- For subjects with a history in the prior year of &lt;2 moderate/severe exacerbations and subjects with a history ≥2 moderate/severe exacerbations, no notable differences were seen within each treatment group in the rate of AEs, SAEs and fatal SAEs (including adjudicated serious adverse reports) and AEs leading to permanent discontinuation of study treatment or withdrawal from the study compared with the ITT Population.
- Of  those subjects with no, 1, or &gt;= to 2 CV risk factors, subjects with &gt;= to 2CV risk factors reported a higher rate of AEs, SAEs and fatal SAEs (including adjudicated serious adverse reports) and AEs leading to permanent discontinuation of study treatment or withdrawal from the study when compared with the ITT Population.
- No notable differences were observed in the incidence and rate of fatal SAEs and adjudicated fatal serious adverse reports for current and former smokers compared with the ITT Population.
- The rate of on-treatment fatal SAEs was higher for subjects with a BMI &lt;25 kg/m2 and subjects with  a  BMI  ≤21  kg/m2  compared  with  the  ITT  Population.    Similar  findings  were  seen  for  on treatment adjudicated fatal serious adverse reports; however, the differences between the rates were  generally  less  pronounced.    The  rate  of  on-treatment  fatal  SAEs  and  on  treatment adjudicated  fatal  serious  adverse  reports  was  lower  for  subjects  with  a  BMI  &lt;25  kg/m2  and subjects with a BMI &gt;21 kg/m2 compared with the ITT Population.
- No notable differences were observed in the rate of any on-treatment fatal SAEs and adjudicated fatal serious adverse reports for subjects with a past history of pneumonia and subjects with no past history of pneumonia compared with the ITT Population.

## Discontinuation due to adverse events

The  incidence  of  on-treatment  AEs  that  led  to  permanent  discontinuation  of  study  treatment  or withdrawal from the study was 6% to 9% across treatment groups with lower exposure-adjusted rates in the FF/UMEC/VI (92.1) group compared with the FF/VI (128.7) and UMEC/VI (144.3) groups.

<div style=\"page-break-after: always\"></div>

Table 31: On-treatment Adverse Events Leading to Permanent Discontinuation of Study Treatment or Withdrawal from the Study in ≥ 1% of Subjects in Any Treatment Group (Study CTT116855, ITT Population).

| Adverse Events Leading to Discontinuation of Study Treatment or Withdrawal from    | FF/UMEC/VI 100/62.5/25 N=4151   | FF/UMEC/VI 100/62.5/25 N=4151   | FF/VI 100/25 N=4134   | FF/VI 100/25 N=4134   | UMECIVI 62.5/25 N=2070   | UMECIVI 62.5/25 N=2070   |
|------------------------------------------------------------------------------------|---------------------------------|---------------------------------|-----------------------|-----------------------|--------------------------|--------------------------|
| the Study System Organ Class Preferred Term                                        | n (%)                           | Rate [#] 1                      | n (%)                 | Rate [#] 1            | n (%)                    | Rate [#] 1               |
| Any Adverse event leading to discontinuation of treatment or withdrawal from study | 252 (6)                         | 92.1 [342]                      | 327 (8)               | 128.7 [445]           | 187 (9)                  | 144.3 [245]              |
| Respiratory, thoracic, and mediastinal disorders                                   | 109 (3)                         | 32.0 [119]                      | 109 (3)               | 32.0 [119]            | 104 (5)                  | 68.9 [117]               |
| COPD                                                                               | 65 (2)                          | 17.5 [65]                       | 93 (2)                | 26.9 [93]             | 72 (3)                   | 42.4 [72]                |

Source:CSR CTT116855RAP Table 3.011

1. Rate was event rate per 1000 subject-years, calculated as the number of events x 1000, divided by the total duration at risk. #=number of event

RAP=Reporting and Analysis Plan

## 2.6.1. Discussion on clinical safety

The safety population supporting the extension of indication comprised a total of 10355 subjects treated with the closed triple combination FF/UMEC/VI 100/62.5/25 for 1 year in Study CTT116855. Different to prior  studies,  patients  with  significant  cardiovascular  (CV)  disease  were  included  in  order  to  allow  an assessment of safety that was more representative of the 'real world' population (e.g. subjects with a past history of previous myocardial infarction [&gt;6 months prior to Screening], New York Heart Association Class  1-3  heart  failure,  and  unstable  or  life-threatening  cardiac  arrhythmia  requiring  intervention  [&gt;3 months prior to Screening] were eligible).

The  incidence  of  CV  risk  factors  was  similar  across  treatment  groups.  Sixty-eight  percent  of  subjects reported  any  CV  risk  factor,  with  40%  of  subjects  reporting ≥ 2  CV  risk  factors.  The  most  frequently reported  CV  risk  factors  were  hypertension  (53%),  hypercholesterolaemia  (33%),  diabetes  mellitus (15%), and coronary artery disease (12%). The percentage of subjects reporting a family history (first degree relatives only) of premature coronary artery disease, myocardial infarction, or stroke was 11% to 16% overall and was similar across treatment groups.

The most frequently reported on-treatment AEs were viral upper respiratory tract infection (URTI) and COPD.  The  incidence  and  exposure-adjusted  rate  of  viral  URTI  were  similar  across  treatment  groups (11% to 13% and 186.7 to 191.9, respectively). The incidence of COPD was 11% in the FF/UMEC/VI and FF/VI groups and 13% in the UMEC/VI group, with a lower exposure-adjusted rate in the FF/UMEC/VI group  (152.9)  compared  with  the  FF/VI  (172.1)  and  UMEC/VI  (207.3)  groups.  Pneumonia  and  oral candidiasis  had  higher  incidences  and  exposure-adjusted  rates  in  the  ICS-containing  groups  (i.e., FF/UMEC/VI and FF/VI) compared with the UMEC/VI group.

ICS-containing treatments are known to increase the risk of pneumonia in COPD patients. This signal was first  identified  in  the  TORCH  study  (Calverley  et  al  2007).  This  was  a  large  clinical  study  of  3  years treatment  duration  comparing  the  fluticasone  propionate/salmeterol  combination  with  its  component parts and placebo in COPD patients. This study was considered in a 2010 review of the risk of pneumonia in COPD patients by the CHMP Pharmacovigilance Working Party that concluded that the treatment with an ICS, either alone or in combination with a LABA, increases the risk of pneumonia in COPD patients. On

<div style=\"page-break-after: always\"></div>

27  April  2015  the  European  Commission  triggered  a  referral  under  Article  31  of  Directive  2001/83/EC resulting from pharmacovigilance data and requested the PRAC to assess the benefit-risk balance of ICS containing  medicinal  products  indicated  in  the  treatment  of  COPD.  The  review  confirmed  the  risk  of pneumonia with these products. The review, however, did not find any conclusive evidence of differences in this risk for different products.

In study CTT116855, as expected there was a higher incidence of pneumonia in the FF/UMEC/VI group (298 subjects [7%]) and in the FF/VI group (264 subjects [6%]) compared with the UMEC/VI group (93 subjects [4%]). The pneumonia event rate per 1000 subjects were 88.6 in the FF/UMEC/VI group and 86.8 in the FF/VI group compared to 57.7 in the UMEC/VI group. The higher risk of pneumonia of about 35%  comparing  FF/UMEC/VI  with  UMEC/VI  has  to  be  taken  into  account  when  balancing  the  benefit against the risk.

When comparing the FF/UMEC/VI and FF/VI groups, the AEs with higher incidences (viral URTI, COPD, URTI,  and  pneumonia)  had  a  similar  risk  for  FF/UMEC/VI  and  FF/VI  groups.  When  comparing  the FF/UMEC/VI and UMEC/VI groups, the risk of COPD was lower for FF/UMEC/VI group while the risk of pneumonia and oral candidiasis was lower for UMEC/VI, as expected based on ICS class effects. While it seems  evident  that  the  triple  combination  was  generally  well  tolerated  when  compared  with  the  dual therapies, the difference in the rates of pneumonia between the ICS- and non ICS-containing arms was evident.  This  reflects  the  known  adverse  event  profile  of  ICS  medications,  and  has  an  impact  on  the substitution potential of the triple therapy versus the LAMA/LABA combinations. Therefore, a paragraph describing the above data on pneumonia is included in section 4.8 of the SmPC.

A total of 244 subjects were reported to have had a fatal SAE (on-treatment and post-treatment). One hundred ninety-three subjects were reported to have had an on-treatment fatal SAE.

On-treatment  fatal  SAEs  were  reported  with  an  incidence  of  2%  in  each  treatment  group  and  with exposure-adjusted  rates  of  26.4,  27.8,  and  38.3  in  the  FF/UMEC/VI,  FF/VI,  and  UMEC/VI  groups, respectively. COPD was the most frequently reported fatal SAE in each treatment group, reported with an incidence of &lt;1% in each treatment group and with exposure-adjusted rates of 3.5, 6.4, and 6.5 in the FF/UMEC/VI, FF/VI, and UMEC/VI groups, respectively. The events in the SOC of Cardiac disorders were reported  with  an  incidence  of  &lt;1%  in  each  treatment  group;  a  lower  exposure-adjusted  rate  was observed  in  the  FF/UMEC/VI  (4.8)  and  FF/VI  (4.6)  groups  compared  with  the  UMEC/VI  (7.7)  group. Nevertheless, no consistent patterns or imbalances were noted across treatment groups when examining the  primary  causes  of  death.  Cardiac  disorders  and  COPD  exacerbation  are  categories  expected  in patients with severe and very severe COPD.

The incidence of on-treatment SAEs (fatal and non-fatal) was similar across treatment groups (21 % to 23% across groups). The most common on-treatment SAEs (fatal and non-fatal) were COPD (11% to 13% across groups) and pneumonia (3% to 4% across groups). The exposure-adjusted rate of COPD was lower for the FF/UMEC/VI (149.1) and FF/VI (164.5) groups compared with the UMEC/VI group (198.4). The exposure-adjusted rate of pneumonia was higher for the FF/UMEC/VI (53.3) and FF/VI (47.7) groups compared with the UMEC/VI group (32.4) as expected.

Two  MACE  analyses  were  performed,  using  broad  and  narrow  MACE  definitions.  The  broad-definition MACE included the ischaemic heart disease SMQ (myocardial infarction SMQ and other ischaemic heart disease  SMQ)  excluding  fatalities,  the  central  nervous  system  haemorrhages  and  cerebrovascular conditions SMQ excluding fatalities, and adjudicated CV deaths. To investigate events relating specifically to myocardial infarction rather than other cardiac ischaemic events, the narrow MACE definition included only  the  PTs  of  non-fatal  myocardial  infarction  and  non-fatal  acute  myocardial  in  addition  to  central nervous system haemorrhages and cerebrovascular conditions SMQ excluding fatalities.

<div style=\"page-break-after: always\"></div>

Any  MACEs  (broad  definition)  were  reported  in  133  (3%)  subjects  in  the  FF/UMEC/VI  group,  in  100 subjects (2%) in the FF/VI group and in 66 subjects (3%) in the UMEC/VI group. The event rate per 1000 subject-year was 44.7 in the FF/UMEC/VI group, 35.3 in the FF/VI group and 44.8 in the UMEC/VI group. Any  MACEs  (narrow  definition)  were  reported  in  80  (2%)  subjects  in  the  FF/UMEC/VI  group,  in  60 subjects (1%) in the FF/VI group and in 37 subjects (2%) in the UMEC/VI group. The event rate per 1000 subject-year was 22.3 in the FF/UMEC/VI group, 18.8 in the FF/VI group and 22.4 in the UMEC/VI group.

Overall, although the rate of cardiac adverse events in all groups were low, particularly in the FF/UMEC/VI group, the results suggest an additive effect when LABA and LAMA are administered together.  Reports of increased risk of such events in patients with COPD who are receiving long-acting bronchodilators  are reported  also  in  the  literature  (e.g.  Wang  MT  et  al.  2018  reported  an  approximate  1.5  fold  increased severe CV risk within 30 days after LABA and LAMA initiation). However at this stage, the CHMP agreed that a specific warning for an additive effect is not warranted and the potential risk of CV effects with LAMA and LABA use is adequately covered by current class labelling for all age groups.  Additionally, no RMP update is considered necessary, however, minor changes have been introduced to the RMP to bring it in line with the new template.

Based on the evaluation of AE data from study CTT116855 six additional ADRs are proposed for inclusion in the FF/UMEC/VI label: bronchitis, sinusitis, urinary tract infection (UTI), constipation, dysphonia, and dry  mouth.  In  addition,  changes  in  frequency  are  proposed  for  two  existing  ADRs  in  the  FF/UMEC/VI label,  based  on  the  frequency  reported  in  Study  CTT116855:  Candidiasis  of  mouth  and  throat  from 'uncommon'  to 'common'  and  Oropharyngeal pain from 'uncommon'  to 'common', respectively. Accordingly, the update of the ADRs section is included in section 4.8 of the SmPC

In study 200812, the safety profile of FF/UMEC/VI in the treatment of COPD subjects was similar to that of FF/VI+UMEC and consistent with previous data for FF/UMEC/VI in a COPD population.

## 2.6.2. Conclusions on clinical safety

As described above, the SmPC is updated in order to reflect either new ADRs or changes in frequency of ADRs in section 4.8, as well as an update on incidence of pneumonia in the clinical studies based on the clinical safety data provided in this application. The changes were considered approvable by the CHMP.

## 2.6.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.7. Risk management plan

Minor changes have been introduced to the RMP to bring it in line with the new template (rev. 2).

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 2.1 is acceptable.

The MAH is reminded that, within 30 calendar days of the receipt of the Opinion, an updated version of Annex I of the RMP template, reflecting the final RMP agreed at the time of the Opinion should be submitted to h-eurmp-evinterface@emea.europa.eu.

The CHMP endorsed this advice without changes.

<div style=\"page-break-after: always\"></div>

The CHMP endorsed the Risk Management Plan version 2.1 with the following content:

## Safety concerns

| Summary of safety concerns   |                                                         |
|------------------------------|---------------------------------------------------------|
| Important identified risks   | Pneumonia                                               |
| Important potential risks    | Serious Cardiovascular Events                           |
| Important potential risks    | Decreased bone mineral density and associated fractures |
| Missing information          | None                                                    |

## Pharmacovigilance plan

There are no on-going or planned additional pharmacovigilance activities for FF/UMEC/VI.

## Risk minimisation measures

| Safety concern                | Risk minimisation measures                                                                                                                                   | Pharmacovigilanceactivities                                                                                                                                                  |
|-------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Pneumonia                     | Routine risk minimisation measures: Section 4.4 and section 4.8 of the SmPC (also Section 4 of Product Leaflet). Additional risk minimisation measures: None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Targeted Follow Up Questionnaire Additional pharmacovigilance activities: None |
| Serious Cardiovascular Events | Routine risk minimisation measures: Section 4.4 and section 4.8 of the SmPC (also Section 4 of Product Leaflet). Additional risk minimisation measures: None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None                             |

<div style=\"page-break-after: always\"></div>

| Decreased Bone Mineral Density and Associated Fractures   | Routine risk minimisation measures: Section 4.4 and section 4.8 of the SmPC (also Section 4 of Product Leaflet). Additional risk minimisation measures: None   | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None   |
|-----------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|

## 2.8. Update of the Product information

Based on the clinical data provided from the clinical studies, several sections of the SmPC are updated. In the indication, the possibility to use Trelegy in patients not adequately treated with a combination of LAMA/ LABA. Additionally, the effect on exacerbations is adequately demonstrated and referent to section 5.1 results are inserted in the indication as mentioned below: (amendments are inserted in track changes)

Trelegy Ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist or a combination of a long-acting β2-agonist and a long-acting muscarinic antagonist (for effects on symptom control and o n exacerbations see section 5.1).

An update of adverse reactions in section 4.8 in agreed upon to reflect new ADRs observed from the clinical data submitted. (see below)

| System Organ Class                            | Adverse reactions                                                                                                                                                       | Frequency   |
|-----------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|
| Infections and infestations                   | Pneumonia Upper respiratory tract infection Bronchitis Pharyngitis Rhinitis Sinusitis Influenza Nasopharyngitis Candidiasis of mouth and throat Urinary tract infection | Common      |
| Infections and infestations                   | Viral respiratory tract infection                                                                                                                                       | Uncommon    |
| Nervous system disorders                      | Headache                                                                                                                                                                | Common      |
| Eye disorders                                 | Vision blurred (see section 4.4)                                                                                                                                        | Not known   |
| Cardiac disorders                             | Supraventricular tachyarrhythmia Tachycardia Atrial fibrillation                                                                                                        | Uncommon    |
| Respiratory, thoracic & mediastinal disorders | Cough Oropharyngeal pain                                                                                                                                                | Common      |
| Respiratory, thoracic & mediastinal disorders | Dysphonia                                                                                                                                                               | Uncommon    |
| Gastrointestinal disorders                    | Constipation                                                                                                                                                            | Common      |

Additionally the warning related pneumonia is updated to reflect the clinical data of the CTT116855. The following paragraph is inserted.

<div style=\"page-break-after: always\"></div>

In a 52-week study, with a total of 10,355 patients with COPD and a history of moderate or severe exacerbations within the prior 12 months (mean post-bronchodilator screening FEV1 46% of predicted, SD 15%) (study CTT116855), the incidence of pneumonia was 8% (317 patients) for Elebrato Ellipta (n = 4,151), 7% (292 subjects) for fluticasone furoate/vilanterol (n = 4,134), and 5% (97 subjects) for umeclidinium/vilanterol (n = 2,070). Fatal pneumonia occurred in 12 of 4,151 patients (3.5 per 1,000 patient-years) receiving Elebrato Ellipta, 5 of 4,134 patients (1.7 per 1,000 patient-years) receiving fluticasone furoate/vilanterol, and 5 of 2,070 patients (2.9 per 1,000 patient-years) receiving umeclidinium/vilanterol.

Finally the section 5.1 is completely updated with the results of the clinical studies described in this application and the results of the PK studies are also included in section 5.2 of the SmPC.

As a consequence of this extension of indication, sections 4.1, 4.8, 5.1, 5.2 and 5.3 of the SmPC have been updated. The Package Leaflet has been updated accordingly.

## 2.8.1. User consultation

The changes to the package leaflet are minimal and do not require user consultation with target patient groups. These changes are acceptable.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

COPD is strongly linked to tobacco smoking, particularly cigarette smoking and is a male predominant condition, in COPD clinical trials in developed countries generally about two thirds of included patients are male and for both males and females the average age tends to be in the early sixties. In poor countries the male predominance is not as marked as women may develop COPD as a result of cooking over open fires. The prevalence is quite variable on a local basis with higher prevalence linked to lower affluence and social status. Screening would be possible by mass measurement of lung function which is cheap, easy, and non-invasive, but is not done in practice. There have been no substantial trials of the value of screening for COPD.  Tobacco smoking cessation or non/never smoking is an effective measure and societal efforts have been made in that direction rather than into screening programmes.

COPD is characterised by cough, excess sputum production, airways narrowing leading to air trapping and hyperinflation of the chest, and loss of lung tissue (emphysema). In its more advanced stages it causes strain and eventually failure, of the cardiac right ventricle.

## 3.1.2. Available therapies and unmet medical need

Management of the condition relies on smoking cessation, pharmacological intervention with bronchodilators and anti-inflammatory agents and, when necessary treatment of respiratory infections, physical rehabilitation is aimed primarily at muscle strengthening, and in advanced cases long term domiciliary oxygen administration is helpful and has a proven benefit on lung function. Some patients are suitable for lung volume reduction surgery to reduce non-gas exchanging thoracic space. Once developed the condition is only partly reversible so more treatment options are always welcome.

<div style=\"page-break-after: always\"></div>

## 3.1.3. Main clinical studies

The main objective of this extension of indication application is to amend the indication of Trelegy Ellipta from the currently approved 'step-up' indication to a more general maintenance in moderate to severe COPD patients thus remove the step up indication. The other changes to the product information are ancillary to this main objective, and are based on the results of the three studies summarised in this report.

The main phase 3 clinical studies supporting this application are one pivotal study CTT116855 and one supportive study 200812. A population PK report is also provided (study 208059).

Study CTT116855 was a randomised, double-blind, parallel-group study that compared the efficacy and safety  of  FF/UMEC/VI  with  FF/VI  and  UMEC/VI  for  52  weeks  in  subjects  with  COPD.  This  study  was designed to evaluate the benefit of FF/UMEC/VI over the FF/VI and UMEC/VI dual component medications in subjects with advanced, symptomatic COPD and at risk of exacerbation using a primary endpoint of the annual rate of on-treatment moderate/severe COPD exacerbations.

Study 200812 was a randomised, double blind, parallel group study comparing FF/UMEC/VI administered in  one  Ellipta  inhaler  with  FF/VI  +  UMEC  administered  in  separate  Ellipta  inhalers  over  24  weeks  in subjects  with  COPD.  This  study  was  designed  to  demonstrate  the  non-inferiority  of  FF/UMEC/VI  to FF/VI+UMEC using a primary endpoint of trough FEV1 at Week 24 with a margin of non-inferiority of 50 mL

The population PK analysis (Study 208059) evaluated combined data from a subset of COPD patients that participated  in  3  phase  IIIa/b  studies  (CTT116855,  CTT116853,  200812)  to characterise  the  PK of  FF, UMEC and VI following administration of FF/UMEC/VI from a single Ellipta inhaler and to assess the effect of covariates on the PK of FF, UMEC and VI.

In  Study  CTT116855,  for  the  primary  endpoint  FF/UMEC/VI  demonstrated  a  statistically  significant reduction in the annual rate of on-treatment moderate/severe exacerbations compared with FF/VI and UMEC/VI   [0.91 (0.87-0.95) in FF/UMEC/VI group, 1.07 (1.02-1.12) in FF/VI group and 1.21 (1.14-1.29) in  UMEC/VI  group  (p&lt;0.001  for  both  comparisons)].  The  effect  of  FF/UMEC/VI  on  the  annual  rate  of moderate/severe  COPD  exacerbations  was  maintained  when  both  on-  and  off-treatment  data  were included in the analysis. For this analysis, FF/UMEC/VI demonstrated a statistically significant reduction in the annual rate of moderate/severe COPD exacerbations compared with FF/VI (11% reduction, p&lt;0.001) and UMEC/VI (20% reduction, p&lt;0.001).

FF/UMEC/VI  demonstrated  a  statistically  significant  reduction  in  the  risk  of  on-treatment  all-cause mortality  compared  with  UMEC/VI  (HR:  0.58;  95%  CI:  0.38,  0.88;  p=0.011,  corresponding  to  a  risk reduction of 42.1%).  For the comparison of FF/UMEC/VI and FF/VI, the risk of on treatment all-cause mortality  was  similar  (HR:  0.95;  95%  CI:  0.64,  1.40,  p=0.780,  corresponding  to  a  risk  reduction  of 5.5%). When both on-and off treatment mortality data were included in the analysis, the significant risk reduction in all-cause mortality was maintained for FF/UMEC/VI compared with UMEC/VI.

## 3.2. Favourable effects

The results of the pivotal trial show that treatment with FF/UMEC/VI results in a significant reduction in the number of moderate or severe exacerbations when compared to either FF/VI or UMEC/VI. There were also significant improvements in many of the other symptomatic and lung function indices studied in the trial as secondary endpoints.

<div style=\"page-break-after: always\"></div>

Overall,  the  data  provided  by  the  MAH  also  support  the  inclusion  of  symptomatic  and  exacerbationrelated text in the indication, and could be used to justify the use of triple therapy as a step-up from ICScontaining dual therapy in patients not controlled on dual therapy.

## 3.3. Uncertainties and limitations about favourable effects

Although the improvement in terms of exacerbations was statistically significantly higher for FF/UMEC/VI compared to the dual combinations (FF/VI and UMEC/VI) the effects were only slightly higher compared to FF/VI. The change compared to FF/VI was 0.16 (model estimated exacerbation rate) and for severe COPD exacerbations showed only a difference of 0.02 compared to FF/VI. The clinical significance of the differences  seen  for  both  moderate  to  severe  and  severe  exacerbations  is  debatable.  Considering  the efficacy and safety, the MAH proposed amendment of the indication to remove the step-up indication is not  supported  at  this  time  based  on  the  submitted  data.    An  alternative  text  has  been  proposed  and accepted, maintaining the step up indication from dual therapies.

## 3.4. Unfavourable effects

The unfavourable effects are those associated with the class of active substances. For the LABA tremor, tachycardia, agitation, increase of blood pressure, hypokalaemia, hyperglycaemia, for the LAMA  dry mouth, blurring of vision, urinary retention, and for the ICS oropharyngeal candidiasis, vocal cord atrophy, hyperglycaemia, and most important pneumonia. They can be expected individually and in combination.

Based on the evaluation of AE data from study CTT116855 six additional ADRs are proposed for inclusion in the FF/UMEC/VI label: bronchitis, sinusitis, urinary tract infection (UTI), constipation, dysphonia, and dry  mouth.  In  addition,  changes  in  frequency  are  proposed  for  two  existing  ADRs  in  the  FF/UMEC/VI label,  based  on  the  frequency  reported  in  Study  CTT116855:  Candidiasis  of  mouth  and  throat  from 'uncommon' to 'common' and Oropharyngeal pain from 'uncommon' to 'common', respectively.

In study 200812, the safety profile of FF/UMEC/VI in the treatment of COPD subjects was similar to that of FF/VI+UMEC and consistent with previous data for FF/UMEC/VI in a COPD population.

Referring to MACE events, from the submitted clinical data there is no evidence of an additive effect when UMEC and VI are administered together.

In study CTT116855, as expected there was a higher incidence of pneumonia in the FF/UMEC/VI group (298 subjects [7%]) and in the FF/VI group (264 subjects [6%]) compared with the UMEC/VI group (93 subjects [4%]). The pneumonia event rate per 1000 subjects were 88.6 in the FF/UMEC/VI group and 86.8 in the FF/VI group compared to 57.7 in the UMEC/VI group. The higher risk of pneumonia of about 35%  comparing  FF/UMEC/VI  with  UMEC/VI  has  to  be  taken  into  account  when  balancing  the  benefit against the risk.

When comparing the FF/UMEC/VI and FF/VI groups, the AEs with higher incidences (viral URTI, COPD, URTI, and pneumonia) had a similar risk for FF/UMEC/VI and FF/VI groups. When comparing the FF/UMEC/VI and UMEC/VI groups, the risk of COPD was lower for FF/UMEC/VI group while the risk of pneumonia and oral candidiasis was lower for UMEC/VI, as expected based on ICS class effects. This reflects the known adverse event profile of ICS medications, and has an impact on the substitution potential of the triple therapy versus the LAMA/LABA combinations. The update on pneumonia is reflected in the SmPC and an updated paragraph is added in section 4.8.

<div style=\"page-break-after: always\"></div>

## 3.5. Uncertainties and limitations about unfavourable effects

Not applicable.

## 3.6. Effects Table

Table 32. Effects Table for Trelegy Ellipta

| Effect               | Short description                       | Unit                 | FF/UMEC/VI           | FF/VI UMEC/VI        | Uncertainties / Strength of evidence                                                    | References           |
|----------------------|-----------------------------------------|----------------------|----------------------|----------------------|-----------------------------------------------------------------------------------------|----------------------|
| Favourable Effects   | Favourable Effects                      | Favourable Effects   | Favourable Effects   | Favourable Effects   | Favourable Effects                                                                      | Favourable Effects   |
| Exacer- bations      | Annual rate of mod/severe exacerbations | Rate                 | 0.91                 | - 1.21               |                                                                                         | Study CTT116855      |
| Trough FEV1          | Change from baseline                    | LS Mean change       | 0.094                | - 0.040              |                                                                                         |                      |
| SGRQ                 | Change from baseline                    | LS Mean change       | -5.5                 | - -3.7               |                                                                                         |                      |
| Unfavourable Effects | Unfavourable Effects                    | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects                                                                    | Unfavourable Effects |
| Pneumon ia           |                                         | n (%)                | 312 (8%)             | 282 (7%) 95 (5%)     | ICS-containing treatments are known to increase the risk of pneumonia in COPD patients. | Study CTT116855      |
| MACE                 |                                         | n (%)                | 80 (2%)              | 60 (1%) 37 (2%)      | There is no evidence of an additive effect when UMEC and VI are administered together.  |                      |

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

For  patients  at  risk  of  COPD  exacerbations,  the  Global  Initiative  for  Chronic  Obstructive  Lung  Disease (GOLD)  strategy  document  for  the  management  of  patients  with  COPD  recommends  an  incremental approach to therapy, beginning with either a LAMA, LAMA/LABA, or ICS/LABA therapy [GOLD, 2017]. If patients  develop  further  exacerbations,  escalation  of  pharmacologic  therapy  is  recommended.  For example, patients on LAMA therapy can be switched to a LAMA/LABA or ICS/LABA with further escalation to triple ICS/LAMA/LABA therapy or those on a dual therapy can be switched to triple therapy if required. This clearly states that triple therapy is currently thought to be best used as an escalation therapy for those incompletely controlled with dual therapy, either ICS/LABA or LABA/LAMA. It does not suggest that patients  with  moderate  to  severe  COPD  should  be  commenced  on  triple  therapy.  That  being  said,  the current  GOLD  guidelines  are  open  regarding  the  evidence  base  on  which  these  recommendations  are based.  As  such,  the  MAH  intention  that  triple  therapy  could  be  used  as  a  first  line  is  not  supported, however the data support amendment of the proposed indication to reflect that it should be used as a step up from LABA/LAMA dual therapy.

Overall,  the  data  provided  by  the  MAH  support  the  inclusion  of  references  to  symptomatic  and exacerbation-related text in  the  indication,  and  could  be  used  to  justify  the  use  of  triple  therapy  as  a step-up  from  both  non  ICS-  and  ICS-containing  dual  therapy  in  appropriate  patients.  Although  the improvement in terms of exacerbations was statistically significantly higher for FF/UMEC/VI compared to the dual combinations (FF/VI and UMEC/VI) the effects were only slightly higher compared to FF/VI. The change  compared  to  FF/VI  was  0.16  (model  estimated  exacerbation  rate)  and  for  severe  COPD exacerbations  showed  only  a  difference  of  0.02  compared  to  FF/VI.  The  clinical  significance  of  the

<div style=\"page-break-after: always\"></div>

differences seen for both moderate to severe and severe exacerbations can be debated.  Considering the efficacy and safety the proposed amendment of the indication is not supported at this time. An alternative text has been agreed as follows: ' Trelegy Ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist or a combination of a longacting β2-agonist and a long-acting muscarinic antagonist (for effects on symptom control and on exacerbations see section 5.1).'

From a safety point of view, concerns regarding the long-term use of ICS medication are well established. These concerns have been reflected in the investigation of newer LABA/LAMA combinations over the recent past, and are further reflected in the GOLD guidelines. Amongst other things, pneumonia is associated with long-term ICS use, and this adverse event was also found in the clinical studies provided by the applicant to support this variation application. Of note, there were significant differences between the rates of pneumonia between the FF/UMEC/VI and UMEC/VI groups, whereas there was no difference between the FF/UMEC/VI and FF/VI groups. This finding suggests that, while there may be a benefit of FF/UMEC/VI over UMEC/VI in terms of the effect on exacerbations, this is offset to some degree by the increased risk of pneumonia in the former. There was no significant difference in the risk of pneumonia between the ICS-containing groups.

## 3.7.2. Balance of benefits and risks

Not applicable.

## 3.8. Conclusions

The overall B/R of Trelegy Ellipta is positive as in patients not adequately treated by a combination of a long-acting β2-agonist and a long-acting muscarinic antagonist treatment. The indication is amended as follows:    ' Trelegy  Ellipta  is  indicated  as  a  maintenance  treatment  in  adult  patients  with  moderate  to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of  an  inhaled  corticosteroid  and  a  long-acting  β2-agonist or  a  combination  of  a  long-acting  β2agonist  and  a  long-acting  muscarinic  antagonist (for  effects  on  symptom  control and  on exacerbations see section 5.1).'

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends, the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

<div style=\"page-break-after: always\"></div>

To modify the approved current COPD therapeutic indication to include the possibility to use Trelegy Ellipta and Elebrato Ellipta as maintenance treatment in patients not adequately treated by dual LABA/LAMA therapy. Additionally cross reference to the effects on symptoms is added. This is based on the results of study CTT116855 and study 200812 and the population PK report 208059. As a consequence, the indication section (4.1), Undesirable effects section (4.8), Pharmacodynamic Properties section (5.1), Pharmacokinetic properties section (5.2) and Preclinical Safety data section (5.3) of the SmPC have been updated. The package leaflet and RMP (v2.1) has been updated accordingly.

The worksharing procedure leads to amendments to the Summary of Product Characteristics and Package Leaflet. A minor amendment in annex II is also introduced to bring it in line with the QRD template.

## Conditions and requirements of the marketing authorisation

## Periodic Safety Update Reports

The marketing authorisation holder shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) ) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Risk management plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

In addition, an updated RMP should be submitted:

At the request of the European Medicines Agency;

Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

To modify the approved current COPD therapeutic indication to include the possibility to use Trelegy Ellipta and Elebrato Ellipta as maintenance treatment in patients not adequately treated by dual LABA/LAMA therapy. Additionally cross reference to the effects on symptoms is added. This is based on the results of study CTT116855 and study 200812 and the population PK report 208059. As a consequence, the indication section (4.1), Undesirable effects section (4.8), Pharmacodynamic

<div style=\"page-break-after: always\"></div>

Properties section (5.1), Pharmacokinetic properties section (5.2) and Preclinical Safety data section (5.3) of the SmPC have been updated. The package leaflet has been updated accordingly.

A minor amendment in annex II is also introduced to bring it in line with the QRD template.  Additionally, minor changes have been introduced to the RMP to bring it in line with the new template (revision 2).

## Summary

Please refer to the published assessment report Elebrato Ellipta-Trelegy Ellipta-WS-1369: EPAR Assessment Report - Variation.